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General introduction – Outline of this thesis 
 
Cancer is one of the most important health problems in our society. Bladder cancer belongs to 
the most common types of cancer in the industrialized areas such as the United States and 
Western Europe. The incidence of bladder cancer increases with age and is 2 to 3 times more 
common in men. This difference is partly explained by differences in cigarette smoking or 
occupational exposure. In the United States, approximately 47,000 men and 16,000 women 
are diagnosed with bladder cancer each year. Bladder cancer is the fourth most common type 
of cancer in men and the eighth most common type in women.  
More than 90% of all malignant bladder tumours are transitional cell carcinomas of which 
two third is superficial and one third is muscle invasive. The superficial transitional cell 
carcinoma of the bladder is characterized by a high risk of recurrence (30-85%) after 
transurethral resection of the initial tumour. This high risk of recurrence makes bladder cancer 
one of the most prevalent human tumours. Patients with a superficial urothelial cell carcinoma 
of the bladder (carcinoma in situ, Ta, T1) can be divided in three groups. A minority of 
patients (20-30%) has a relatively benign type of transitional cell carcinoma, with a low 
recurrence rate. These low risk tumours do not exhibit progression. In such patients 
transurethral resection followed by one immediate instillation with a chemotherapeutic agent 
is the treatment of choice. This adjuvant treatment after apparently complete tumour resection 
is given in order to prevent tumour cell implantation and subsequent recurrence by that 
mechanism. This treatment reduces the recurrence rate with 50% in the first year, nearly 
without any side effects. This policy is safe and effective. Currently there is no need for new 
treatment options in patients with such low risk tumours.  
The second and also largest group (40-50%) is patients with intermediate risk tumours. These 
patients often develop a superficial recurrence, but seldom progression. In an attempt to 
reduce the number of recurrences, a series of intravesical instillations with a chemotherapeutic 
agent is given post-operatively. This prophylactic treatment has a limited number of side 
effects, but the long term recurrence rate (>5 years) is subsequently less than 10%. That is 
why more active treatment options with preservation of the low toxicity profile are needed.  
Finally, a small group of patients (20-30%) has a relatively aggressive superficial tumour at 
presentation and despite maximum intravesical treatment, 70% to 80% of these patients will 
have recurrent disease. After all, 30% to 50% will develop a muscle invasive disease.  
 13
Chapter 1 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
The treatment of muscle invasive bladder cancer (cystectomy) is completely different than the 
treatment of the superficial type of bladder cancer (transurethral resection and instillations). 
Furthermore, patients with a tumour that has become invasive have a very bad prognosis. The 
three years tumour specific survival is 37% compared to a five years tumour specific survival 
of 90% in the superficial disease. These high risk patients must be treated with the most 
effective drugs. Currently, BCG instillations are the most effective. This treatment is more 
effective than intravesical chemotherapy, but has more and more frequent side effects. 
Therefore, there is a need for more effective treatment options or treatment options with less 
and less severe side effects. 
In this thesis, the results of new treatment options for patients with intermediate or high risk 
superficial bladder cancer are discussed.  
The different chemotherapeutical modalities currently used and investigated for the treatment 
of transitional cell carcinoma of the bladder are reviewed in chapter 2, starting with the first 
drug shown to be effective for the treatment of superficial bladder cancer and chronologically 
leading to the latest treatment options. 
In chapters, 3, 4 and 5 the results of basic and preclinical therapeutical studies are discussed. 
In chapter 3, the cytotoxic effect of thermo-chemotherapy is studied. Although it is possible 
that the effect of mitomycin-C (MMC) is enhanced by an increased absorption, increased 
MMC metabolism or inhibition of DNA repair, the exact mechanism of this combination 
therapy is still not clear. In this chapter the differences in cytotoxicity of four 
chemotherapeutic agents combined with hyperthermia is studied. In this in vitro study human 
bladder cancer cell lines underwent thermo-chemotherapy.  The effect of direct cell contact of 
several chemotherapeutic agents combined with hyperthermia is determined and compared.  
The results of a preclinical animal study with gemcitabine are discussed in chapter 4. 
Gemcitabine has been shown to be effective and well tolerated when given systemically. In 
advanced bladder cancer patients gemcitabine appears to be one of the most effective drugs 
available. To test the potential and risks of gemcitabine when used intravesically, a pig 
experiment is designed in which the pharmacokinetics of gemcitabine and histological 
urothelial changes are studied. This animal study preceded the phase I study described in 
chapter 6. 
Chapter 5 describes the histological changes of the urothelium due to chemotherapy, 
hyperthermia and thermo-chemotherapy. Fifteen patients who underwent cystectomy were 
included in this comparative descriptive study. Patients were treated with thermotherapy, 
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chemotherapy or thermo-chemotherapy. The influence on the urothelium of the various 
treatments was investigated by several immunohistochemical stainings.  
The results of the clinical studies concerning new treatment options are discussed in chapter 6, 
7 and 8. In the phase I gemcitabine study, chapter 6, results of 3, 4 and 3 intermediate or high 
risk patients treated with 1000, 1500 and 2000 mg gemcitabine are described. In this clinical 
study the maximum tolerated dose intravesical gemcitabine, the side effects and the 
pharmacokinetics are studied. 
The results of the phase II marker lesion study with intravesical instillation of EOquinTM 
(EO9) in intermediate or high risk superficial bladder cancer are described in chapter 7. EO9 
has proven to be effective against transitional cell carcinoma of the bladder (in cell cultures 27 
times more effective than MMC). The rapid clearance from the blood stream (t½<10 minutes) 
which must contribute to its rapid pharmacokinetic elimination in vivo makes EO9 inadequate 
for intravenous application, but very appropriate for intravesical use. In this study all patients 
with multiple tumours underwent a transurethral resection of all tumours except one marker 
tumour measuring between 0.5 and 1.0 cm. Subsequently, patients are treated with six weekly 
intravesical EO9 instillations. Response was determined two to four weeks after the last 
instillation. Complete response was defined as complete destruction of the marker lesion, 
confirmed by negative biopsy at the site of the marker tumour, and the appearance of no new 
tumours elsewhere. The incidence of side effects was scored and compared to previously 
reported side effects of MMC, epirubicin and BCG.  
In chapter 8, the results of a phase III thermo-chemotherapy study are described. This novel 
treatment option in patients with intermediate to high risk tumours is the combination of 
intravesical hyperthermia and intravesical chemotherapy (Synergo® treatment). In several 
tumours thermo-chemotherapy works synergistically. The effect of MMC improves 
significantly when hyperthermia is added. Ninety patients with intermediate to high risk 
tumours are included. After transurethral resection all patients underwent prophylactic 
thermo-chemotherapy treatment. The results of patients who are BCG failures are compared 
to the results of BCG naïve patients. Furthermore, all results are compared to recent literature 
data. In the appendix of chapter 8, the results of patients with high grade (GIII) bladder 
tumours treated with thermo-chemotherapy in an ablative or prophylactic schedule are 
discussed. Results of both treatments are evaluated. 
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Algemene inleiding – Overzicht van deze thesis 
 
Kanker is in onze maatschappij een van de grootste gezondheidsproblemen. Blaaskanker 
behoort vooral in de geïndustrialiseerde gebieden zoals de Verenigde Staten en West Europa 
tot een van de meest voorkomende vormen van kanker. De incidentie van blaaskanker neemt 
toe met de leeftijd en komt twee tot drie keer vaker voor bij mannen dan bij vrouwen. Dit 
verschil is deels te verklaren door het rookgedrag en het arbeidsverleden van de mannen. In 
de Verenigde Staten bijvoorbeeld worden jaarlijks ongeveer 47.000 mannen en 16.000 
vrouwen gediagnosticeerd met blaaskanker. Blaaskanker is daarmee de vierde meest 
voorkomende vorm van kanker bij mannen en de achtste meest voorkomende vorm bij 
vrouwen.  
Meer dan 90% van alle maligne blaastumoren zijn urotheelcelcarcinomen waarvan ongeveer 
tweederde oppervlakkig en eenderde spierinvasief is. Het oppervlakkige urotheelcelcarcinoom 
van de blaas wordt gekenmerkt door een hoge recidiefkans (30-85%) na transurethrale 
resectie van de tumor. Deze hoge recidiefkans maakt blaaskanker een van de meest prevalente 
humane tumoren.  
Patiënten met oppervlakkige urotheelcelcarcinomen van de blaas (carcinoma in situ, Ta, T1) 
kunnen worden onderverdeeld in 3 groepen. Een minderheid (20%-30%) heeft een weinig 
agressieve vorm van het urotheelcelcarcinoom, met een laag recidief percentage, zogenaamde 
laag risico tumoren. Deze tumoren vertonen geen progressie. Behandeling in deze groep 
patiënten bestaat uit een transurethrale resectie gevolgd door een directe instillatie met een 
chemotherapeuticum. Deze zogenaamde adjuvante behandeling na complete resectie wordt 
gegeven om tumorcelimplantatie en dientengevolge recidivering te voorkomen. Deze 
behandeling verkleint de recidiefkans in het eerste jaar met 50%, nagenoeg zonder 
bijwerkingen. Dit beleid is veilig en effectief. Momenteel is er dan ook geen noodzaak tot 
nieuwe ontwikkelingen voor de behandeling van patiënten met laag risico tumoren.  
De tweede en tevens grootste groep (40 tot 50%) wordt gevormd door patiënten met 
intermediair risico tumoren. Deze patiënten ontwikkelen wel oppervlakkige recidieven, maar 
vertonen zelden progressie. In een poging om het aantal recidieven te beperken wordt 
postoperatief een serie intravesicale spoelingen met een chemotherapeuticum gegeven. Deze 
profylactische behandeling heeft weliswaar een beperkt aantal bijwerkingen, maar de recidief 
reductie op lange termijn (>5 jaar) is ook minder dan 10%. Zodoende zijn actievere 
medicijnen met behoud van het lage toxiciteitprofiel nodig.  
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Ten slotte is er nog een kleine groep patiënten (20%-30%) met een relatief agressieve 
oppervlakkige tumor bij diagnose die ondanks maximale intravesicale behandeling bij 70%-
80% van de patiënten kan recidiveren. Van deze hoog risico patiënten ontwikkelt 30 tot 50% 
een spierinvasieve tumor. Spierinvasieve blaaskanker wordt volstrekt anders behandeld 
(cystectomie) dan de oppervlakkige vorm van blaaskanker (transurethrale resecties en 
instillaties). Bovendien hebben patiënten met een tumor die spierinvasief is geworden een 
zeer slechte prognose. De drie jaar tumor specifieke overleving is 37% vergeleken een vijf 
jaar tumor specifieke overleving van 90% bij oppervlakkige ziekte. Deze hoog risico 
patiënten moeten met de meest effectieve medicijnen worden behandeld. Thans zijn 
intravesicale BCG spoelingen het meest effectief. Deze behandeling is effectiever dan 
intravesicale chemotherapie, echter met frequentere en ernstigere bijwerkingen. 
Dientengevolge is er behoefte aan effectievere behandelmethoden of behandelmethoden met 
minder frequente en minder ernstige bijwerkingen. 
In deze thesis worden de resultaten gepresenteerd van nieuwe behandelmethoden voor 
patiënten met een intermediair of hoog risico oppervlakkige blaastumor. Allereerst worden in 
hoofdstuk 2 alle thans gangbare behandelmethoden in chronologische volgorde besproken.  
In de hoofdstukken 3, 4 en 5 worden de resultaten besproken van preklische en basaal 
wetenschappelijke studies. In hoofdstuk 3 wordt het cytotoxische effect van 
thermochemotherapie bestudeerd. Hoewel het mogelijk is dat het effect van Mitomycine-C 
(MMC) versterkt wordt door toegenomen absorptie, toegenomen MMC metabolisme of 
remming van DNA herstel, is het exacte mechanisme van de combinatie hyperthermie en 
chemotherapie nog niet duidelijk. In dit hoofdstuk wordt hyperthermie in combinatie met een 
van vier frequent intravesicaal gebruikte chemotherapeutica bestudeerd. Het betreft een in 
vitro studie waarbij humane blaaskankercellijnen thermo-chemotherapie ondergaan. De 
effectiviteit van de diverse middelen bij direct celcontact in combinatie met hyperthermie 
wordt geanalyseerd. 
In hoofdstuk 4 worden de resultaten van een dierexperimentele gemcitabine studie 
besproken. Gemcitabine bleek bij systemische toepassing in mensen een substantiële activiteit 
tegen invasieve urotheelcelcarcinomen te hebben. De intravesicale toepassing wordt in dit 
varkensmodel getoetst. Bovendien worden de pharmacokinetiek van gemcitabine en de 
eventuele histologische urotheelveranderingen bestudeerd. Deze dierexperimentele studie is 
voorafgegaan aan de fase I studie die beschreven wordt in hoofdstuk 6.  
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In hoofdstuk 5 worden de histologische veranderingen aan het urotheel ten gevolge van 
chemotherapie, hyperthermie en thermo-chemotherapie beschreven om zo eventuele voor- en 
nadelen van de diverse therapieën duidelijk te krijgen. In deze vergelijkende beschrijvende 
studie zijn 15 patiënten ingesloten die een cystectomie hebben ondergaan. Deze patiënten zijn 
voorbehandeld met thermotherapie, chemotherapie of thermo-chemotherapie. De invloed van 
de diverse behandelingen op het urotheel wordt bestudeerd met gebruikmaking van diverse 
immunohistochemische kleuringen. 
In de hoofdstukken 6, 7 en 8 worden de resultaten van de klinische studies naar nieuwe 
behandelmethoden beschreven. Hoofdstuk 6 beschrijft de resultaten van de fase I studie met 
gemcitabine. In deze studie zijn 3, 4 en 3 intermediair- of hoogrisico patiënten behandeld met 
een serie van zes spoelingen met 1000, 1500 of 2000 mg gemcitabine. In deze patiëntenstudie 
wordt gekeken naar de maximaal toelaatbare intravesicale dosering gemcitabine, de 
bijwerkingen en de pharmacokinetiek.  
In hoofdstuk 7 worden de resultaten van een fase II markerlaesie studie naar intravesicale 
EOquinTM (EO9) bij patiënten met intermediair- of hoogrisico tumoren beschreven. EO9 is 
bewezen effectief tegen o.a. het urotheelcelcarcinoom (in celkweken 27 keer effectiever dan 
MMC). De korte halfwaardetijd in bloed (t½<10 minuten) maakt het ongeschikt voor 
intraveneus gebruik, maar juist uitermate geschikt voor toepassing in de blaas. In deze studie 
is bij alle patiënten met multiple blaastumoren tijdens transurethrale resectie een blaastumor 
met een diameter van 5 tot 10 mm als markerlaesie achtergelaten. Vervolgens zijn patiënten 6 
keer wekelijks behandeld met EO9 spoelingen. De respons wordt twee tot vier weken na de 
laatste instillatie vastgesteld. Complete respons is gedefinieerd als de complete verdwijning 
van de markerlaesie, bevestigd door een negatief biopt en geen nieuw ontstane tumoren elders 
in de blaas. De incidentie van bijwerkingen wordt gescoord en vergeleken met eerder 
gepubliceerde cijfers met betrekking tot bijwerkingen van MMC, epirubicine en BCG 
In hoofdstuk 8 worden de resultaten van een Europese multicenter studie naar thermo-
chemotherapie beschreven. Deze nieuwe behandelmethode bij patiënten met een intermediair 
of hoogrisico tumor is een combinatie van intravesicale hyperthermie en intravesicale 
chemotherapie (Synergo® behandeling). In diverse tumoren werkt thermochemotherapie 
synergistisch. Hyperthermie verbetert significant de effectiviteit van MMC. Negentig 
patiënten met een intermediair- of hoogrisico tumor zijn ingesloten. Na transurethrale resectie 
ondergingen alle patiënten profylactisch thermo-chemotherapie. De resultaten van patiënten 
waarbij eerdere BCG behandelingen niet voldoende effectief waren worden vergeleken met 
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de resultaten van BCG naïeve patiënten. Tevens worden alle resultaten vergeleken met 
resultaten uit de recente literatuur. In het appendix van hoofdstuk 8 worden de resultaten 
beschreven van een studie naar patiënten met een hooggradige (GIII) blaastumor behandeld 
met thermochemotherapie. Deze patiënten zijn behandeld in een ablatief schema of 
profylactisch schema afhankelijk van het feit of zij een volledige transurethrale resectie 
hebben ondergaan. De resultaten van beide behandelingen worden geëvalueerd.  
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Abstract 
 
More than 90% of all malignant bladder tumours are transitional cell carcinomas (TCC) of the 
bladder. Superficial TCC of the bladder is characterized by a high risk of recurrence (30-85%) 
after transurethral resection (TUR) of the initial tumour. Despite this high risk of recurrence, 
the 5-year survival rate is 85% to 90%. Unfortunately, 10 to 30% of the superficial tumours 
will progress to a muscle invasive tumour, which has a poorer prognosis. The greatest concern 
in patients with superficial TCC is therefore twofold: to lower the number of recurrences and 
to prevent progression.  
In an attempt to prevent or delay tumour recurrence or progression, adjuvant therapy after 
TUR has become common practice. The different chemotherapeutical modalities currently 
used and investigated for the treatment of TCC of the bladder are reviewed, starting with the 
first drug shown to be effective for treatment of superficial bladder cancer and 
chronologically leading to the latest treatment options.  
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Introduction 
 
Superficial transitional cell carcinoma (TCC) of the bladder is characterized by a high risk of 
recurrence (30-85%) after transurethral resection (TUR) of the initial tumour1;2.  
Clinical prognostic factors for recurrence and progression are size, multiplicity, reaction to 
intravesical therapy, grade, stage and the presence of CIS. Nevertheless, recurrence anywhere 
in the bladder at first follow-up cystoscopy after TUR is one of the most important prognostic 
factors for time to progression3;4. 
It is possible to identify three groups of patients. A minority of patients has a relatively benign 
type of TCC, with a low recurrence rate. In such patients refraining from adjuvant treatment is 
an option, but one immediate instillation with a chemotherapeutic agent lowers the recurrence 
rate in the first few years significantly5-7, and therefore is the treatment of choice.   
The largest group consists of patients who develop a superficial recurrence, but seldom 
progression. In an attempt to reduce the number of recurrences, adjuvant therapy after TUR 
has become common practice. 
Finally, a small group of patients has a relatively malignant superficial tumour at presentation 
and despite maximum intravesical treatment, 50% of all patients will develop invasive cancer. 
These high risk patients must be selected as soon as possible.  
 
 
Principles of intravesical prophylaxis and therapy  
 
The aim of intravesical treatment in superficial bladder cancer is to prevent or delay tumour 
recurrence or progression. The mechanism of action for prophylactic intravesical chemotherapy 
remains unclear. Even though topical immuno- and chemotherapy may be useful to delay 
recurrence and progression, chromosomal patterns remain basically unstable8. 
Because most chemotherapeutic drugs are cell cycle specific, repeated instillations seem to be 
more effective than a single one.  
The drug is dissolved in sterile water, which provides better results as a diluent than saline9. 
The effect of the pH of the solution is not clear. Theoretically, the pH can influence the 
stability and efficacy of the drug. An in vitro study, for example, showed that the cytotoxic 
activity of ThioTEPA was markedly enhanced when cells were treated with a diluent pH of 
5.5. Significant differences were also observed after treatment with adriamycin (ADM) and 
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mitomycin-C (MMC) with a diluent pH of 7.010. Wientjes and Badalament11 used 
pharmacokinetic data to develop a computer model which can predict the antitumour effect of 
MMC. The therapeutic outcome of MMC was influenced in the following rank order:  dose> 
residual volume> urine production> dosing volume> urine pH> dwell time. They 
hypothesized that under optimal conditions the average recurrence free rate could increase 
from 56% to 76%.  
Before instillation the patient is advised to limit fluid intake in order to minimize dilution of 
the drug with urine. Systemic absorption is possible when the urothelium is damaged. In case 
of trauma or infection, instillation should be postponed for one week. The instillation is left 
for 1 to 2 hours in the bladder. Although cytotoxicity is proportional to drug concentration 
and exposure time, longer instillation time might increase toxicity and is unpractical12.  
An advantage of the intravesical administration route is no or little systemic uptake of the 
drug and direct contact between tumour or urothelium at risk, and the drug. Disadvantages are 
local side effects and the need for transurethral manipulation.      
 
 
ThioTEPA 
 
ThioTEPA was the first drug shown to be effective for treatment of superficial bladder cancer 
when given intravesically13. The disadvantage is the low molecular weight which enables it to 
pass through the bladder wall easily14;15. However, myelosuppression is considered to be rare, 
usually mild and transient16. Trasher et al. reviewed the toxicity of ThioTEPA17. They 
concluded that the risk of myelosuppression and irritative complaints increased with the dose 
and with the number and frequency of instillations.  
ThioTEPA is better than no additional therapy, although not always statistically significant18-20. 
ThioTEPA is no longer frequently used due to its (systemic) toxicity and limited efficacy.  
 
 
Ethoglucid (Epodyl) 
 
Epodyl has a molecular weight of 262 and is thus poorly absorbed. Drug induced cystitis; 
dysuria and frequency are the most common side effects17. Kurth et al. compared the efficacy 
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of TUR with TUR followed by 1 year ADM or ethoglucid21. The recurrence rate per year was 
0.30 for both adjuvant treatment arms and 0.68 for the group only receiving TUR (p<0.001).  
Long-term follow-up was studied in 111 patients retrospectively with 6.4 years follow-up22. 
In total 65% of all patients responded completely after 12 weekly instillations and 46% of 
these remained free of disease for 5 years. Currently, Epodyl is not frequently used anymore. 
 
 
Adriamycin (Doxorubicin, ADM) 
 
The molecular weight of ADM is 580, thus absorption and systemic toxicity are extremely 
rare. The most frequent side effect of ADM is chemical cystitis in 25-30% of the patients17. 
The response rates of ADM used as definite treatment for papillary tumours varies between 28 
and 56%, with an average of 38% (273/712), depending on the dose used19. However, for CIS 
the complete response is only 34% in a multicentre trial with 67 CIS patients23. 
Lamm reviewed 4 large controlled studies where ADM was used as prophylactic. The 
percentage of patients with a recurrence in the ADM groups was 38%, versus 56% in the control 
groups, indicating an advantage for ADM of 18%24. Nevertheless, the three largest series showed 
no significant advantage for ADM25. In an attempt to improve the ADM treatment Naito et al. 
performed a randomized controlled trial in which ADM treatment was compared with ADM 
combined with verapamil26. The ADM plus verapamil instillation group did show a significantly 
higher no recurrence rate than the ADM instillation group.    
The Japanese urological cancer research group studied the possible advantages of 
maintenance therapy and found no advantage27. In conclusion, ADM is a safe drug with almost 
no systemic side effects. ADM is more effective than no adjuvant treatment, but again these 
figures often are not significant.  
 
 
Epirubicin (EPI) 
 
The antitumour effect of EPI is similar to ADM28. Absorption of EPI, even when EPI is given 
immediately after TUR29, is very limited due to a molecular weight of 544. The most frequent 
side effect is chemical cystitis. Burk et al. reported that 14% of patients in a large series had 
chemical cystitis30.  
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The EPI dose is controversial. In a randomized UK study the marker tumour response, time to 
first recurrence or recurrence rate at 50 mg/50 mL is equal to the response at 100 mg/50 mL31;32.  
Rajala et al. studied the effect of a single instillation with EPI. In this trial the long-term efficacy 
of a single dose of 100 mg EPI administered immediately after TUR was compared with TUR 
alone for primary TCC in 200 patients33. At a median follow-up of 72 months the recurrence rate 
was 46% for patients treated with EPI and 73% for the control group (p = 0.002), so a single 
perioperative instillation of 100 mg epirubicin causes a significant decrease in recurrence rate. 
Similar results were found using a much lower dose of 40 mg/40 mL EPI in 119 patients34. With 
regard to maintenance therapy many studies have been performed. Eto et al. compared EPI to 
ADM35. The differences in tumour free rates at 1 and 2 years were not significant.  
In a maintenance study with EPI the overall recurrence rate was 23.9% at 2 years and 47.7% at 5 
years follow-up. These results were better than patients treated with TUR alone36. Torelli showed 
also that maintenance treatment with EPI can be effective37. Nevertheless, another study with a 
similar treatment schedule suggested that maintenance therapy did not improve the efficacy38. 
A possible explanation is the use of a lower dose of EPI. 
In conclusion, the efficacy of EPI seems similar to other chemotherapeutic drugs, however, with 
less drug induced cystitis. The additional advantage of EPI maintenance therapy is controversial. 
 
 
Mitomycin-C (MMC)  
 
MMC has an intracellular effect resulting in the production of an alkylating agent. The mode 
of action is poorly understood. With a molecular weight of 334 MMC is hardly absorbed so 
myelosuppression is rare (0.7%). In a meta-analysis the mean incidence of frequency is 42%, 
bacterial cystitis 20% and allergic (skin) reactions 13%39.  Most skin reactions are due to a 
delayed type hypersensitivity reaction, usually occurring after several instillations40. 
In an EORTC marker lesion study (30864), the complete response rate for the marker lesion after 
8 instillations with 80 mg of MMC was 50% (48/96)19.  
The effectiveness of a single immediate MMC instillation in patients with low risk superficial 
bladder cancer was studied in a prospective controlled trial by Solsona et al.6. In this study 64 
patients received no treatment and 57 received one immediate instillation of 30 mg MMC after 
complete TUR. Recurrences developed during the first 12 months in 59% of the control group 
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but only 22.2% of the MMC group (p=0.005). However, at long-term follow-up these 
differences were not statistically significant. 
For prophylactic use, after complete TUR, data from 23 clinical trials were analyzed and 
confirmed that the average net benefit from intravesical chemotherapy compared to TUR 
alone was 14% at 1 to 3 years41. Lamm also reviewed five controlled prophylactic trials with 
859 patients24. The advantage of MMC was 15%. 
The long-term follow-up was also studied in a prospective EORTC study. The efficacy with 
regard to tumour recurrence was similar for patients treated with 6 weekly MMC instillations 
and 6 weekly BCG-RIVM instillations42. In another study 9 weekly MMC instillations were 
compared with 6 weekly BCG-Tice or BCG-RIVM instillations43. The disease-free 
percentage showed no difference for the three arms for papillary tumours (P=0.08), nor for 
CIS (P=0.20). However, studies directly comparing BCG and MMC give conflicting results. 
Two possible causes might be patient selection and the use of different MMC and especially 
BCG schedules. 
In an attempt to improve the MMC treatment Au et al. performed a randomized 2-arm study 
(119/111), in which instillation of 40 mg MMC with pharmacokinetic intervention to increase 
drug concentration by decreasing urine volume, was compared with 20 mg MMC instillation 
without intervention. After 5 years follow-up, the optimized arm showed a time to recurrence 
of 29.1 months and a recurrence-free fraction of 41.0%, versus 11.8 months and 24.6%  
(P<0.005) for the normal treatment44. 
The advantage of MMC maintenance therapy is controversial. The results of a Japanese study 
showed no advantage for maintenance therapy over short-term therapy45. Nevertheless, some 
studies did show an advantage of maintenance therapy46-48. A possible explanation for this 
contrariety is found in a pair wise comparison which showed that a combination of a short-term 
intensive (weekly) instillation schedule combined with long-term maintenance instillation was 
significantly more effective as compared to long-term maintenance instillation alone48. In other 
words the effect of the short-term intensive MMC therapy may be of more importance than the 
long-term maintenance therapy. 
Finally, several studies compared maintenance MMC with maintenance BCG49;50. In one study, 
the relative risk of recurrence, despite MMC (0.508) or BCG (0.618), was similar49. 
Nevertheless, in a prophylactic study of Malmstrom, maintenance BCG was superior in 
preventing recurrence compared to maintenance MMC, but no difference was found for 
progression and survival50.  
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In conclusion, the response rates of MMC seem higher than those of other chemotherapeutic 
drugs. However, once again, not all studies show a significant advantage of MMC over no 
additional treatment. The advantage of MMC maintenance therapy is again controversial.  
 
 
Valrubicin (AD32) 
 
Valrubicin (AD32) is an N-trifluoroacetyl, 14-valerate derivative of the anthracycline ADM51. In 
patients with BCG-refractory CIS or recurrent papillary tumours of the bladder that have failed 
other intravesical therapies and refuse cystectomy, AD32 has been used in 90 patients who 
received 6 weekly instillations of 800 mg AD3252. Of all patients 21% had a complete response. 
Additionally, 16% had Ta recurrence only.  
In a marker lesion study with AD32, 54% were found clinically free of disease, whereas 46% 
were found histologically free of disease after 3 months53.  
Adverse events were assessed in a pilot study including 22 patients who received a single dose of 
valrubicin54. The most commonly reported events were dysuria (77%), haematuria (59%) and 
urgency/frequency (23%). Additional follow-up and more studies are needed to define the role of 
valrubicin in the treatment of superficial bladder cancer. 
 
 
Pirarubicin (THP) 
 
Another anthracycline under investigation is pirarubicin. An initial study comparing 20 mg of 
ADM, EPI, pirarubicin and a control group, showed no significant difference in efficacy for the 
three drugs used, although pirarubicin failed to show a significant advantage over the control 
group55. However, a few years later, the optimal dose in terms of anti-tumour effect and minimal 
side effects was found to be 30 mg/30 mL during 30 minutes56. In a randomized study of single 
early THP instillation for a single superficial bladder carcinoma 84 patients were treated with 
either THP within 6 hours after TUR versus the controls who underwent TUR alone57.The 
recurrence free rate at 1 year was 92% versus 67%, and 79% versus 53% after 3 years. This 
indicates that a single THP instillation immediately after TUR reduces the recurrence of TCC.  
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Gemcitabine 
 
Gemcitabine is a novel deoxycytidine analogue with a broad spectrum of antitumour activity. 
It has a molecular weight of 300 and after intracellular activation, the active metabolite is 
incorporated into DNA, resulting in inhibition of further DNA synthesis. One animal study 
with safety data on the intravesical use in dogs is published in 199958. In this study at all 
intravesical doses, significant systemic absorption was seen. However, preclinical results of 
our own department show no systemic absorption in pigs59. A possible explanation is the 
difference in the instillation schedule (three times a week versus weekly). This will be 
discussed more extensively in chapter 4 of this thesis. 
In a phase I trial performed in our hospital, 3, 4 and 3 patients were treated with 1000, 1500, 
and 2000 mg gemcitabine in 50 mL saline respectively. Seven patients experienced mild 
transient side effects. Gemcitabine plasma levels were immeasurable or low, with peak levels 
between 30 and 60 minutes (see chapter 6 of this thesis). Thus intravesical gemcitabine in the 
dose used has minimal and reversible side effects and plasma evaluation indicates that its 
intravesical use is safe. Additionally, the preliminary results in twelve other small studies (in 
total 142 patients including patients with BCG refractory CIS60) also show practically no 
systemic toxicity (personal communication).  
 
 
EOquinTM (EO9) 
 
EO9 belongs to a group of novel anti-cancer agents known as bioreductive drugs. These drugs 
are inactive prodrugs which require activation by cellular reductase enzymes in order to 
become toxic to the cell. In the case of EO9, the enzyme DT-diaphorase plays a central role in 
activating the drug. However, under hypoxic conditions, EO9 is activated also in cells lacking 
expression of DTdiaphorase. Chemo sensitivity data of our own in vitro work shows that 
depending on the type of human bladder cancer cell line used, the concentration EO9 to reach 
LD50 was 6 to 78 times lower than the concentration MMC (see also chapter 3 of this thesis). 
EO9 has undergone clinical evaluation against a range of tumour types but failed to 
demonstrate activity when the drug was administered into the blood stream. Based upon 
several studies of Loadman et al. at the University of Bradford, it would appear that the main 
reason for EO9’s failure in the clinical setting is poor delivery. The basis for this hypothesis 
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stems from the fact that EO9 is rapidly removed from the blood stream (half life < 10 min) 
and poor penetration through avascular tissue. While these properties of EO9 are a problem in 
terms of treating systemic disease, they may paradoxically be ideal for treating cancers which 
arise in an anatomically accessible site such as the bladder. In this case, drug delivery to the 
tumour is not a problem as drugs are routinely placed in the bladder using a catheter. Any 
drug reaching the blood stream would be rapidly removed and therefore the risk of toxic side 
effects to other organs and tissues would be low.  
In a phase I marker lesion study, six patients were treated with an escalating dose EO9 (0.5 to 
16 mg). After a median follow-up period of more than 15 months 4 patients were still free of 
recurrences. In the same study also 6 patients were treated with a fixed dose of 4 mg EO9. 
Four out of six patients were complete responders after 6 consecutive treatments. After a 
mean follow-up of 9 months the four patients were still free of recurrences. In a phase II 
marker lesion study the efficacy of EO9 will be studied (chapter 7 of this thesis). 
 
 
Sequential chemo/immunotherapy 
 
The theoretical advantage of sequential use of chemotherapy and immunotherapy might be the 
combination of different working mechanisms with possible potentiation of antitumour effect. A 
second advantage might be the increase in the fibronectin activity61 due to chemical cystitis 
which can have a positive effect on the adherence of BCG particles to the bladder wall62. A 
disadvantage could be that the intravesical combination of a chemotherapeutic drug and BCG 
might also enhance toxicity. 
An EORTC marker lesion study (30897) with sequential MMC and BCG (4 times versus 6 
times), for low stage, low grade recurrent bladder tumours, gave a complete response of 69%63. 
The Finnbladder group conducted 2 studies comparing MMC with an alternating MMC/BCG 
schedule in patients with CIS64 or rapidly recurring papillary tumours65. In both studies the side 
effects in the MMC/BCG group were similar to those in the MMC group. In CIS patients the 
alternating schedule was significantly more effective than MMC alone with regard to the CR rate 
(74% versus 47% at 24 months, p=0.041), disease free interval (p=0.043) and recurrence rate 
(p=0.013). Efficacy results in papillary tumours were equal in both arms65. 
Results from a study of our own department showed that the sequential use of intravesical BCG 
and MMC had no advantage over intravesical MMC alone in intermediate and high risk 
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superficial bladder cancer patients with regard to tumour recurrence and progression66. This 
difference can be explained by the fact that only 4% of all patients in our group had CIS, where 
the Finnbladder group considered the alternating schedule to be more effective. 
 
 
Intravesical hyperthermia and mitomycin-C 
 
Intravesical hyperthermia has been used to improve the efficacy of MMC. A study to assess 
the effect of local hyperthermia on systemic absorption of MMC during intravesical 
chemotherapy showed that the MMC plasma concentration was always 6 times lower than 
those to show myelosuppression67. 
Colombo et al. studied microwave induced hyperthermia and intravesical chemotherapy. In a 
neoadjuvant study pathologically complete response was seen in 66% of all patients. Another 
neoadjuvant study showed 47% complete and 37% partial responders69.  
In a prospective multicentric randomized trial 83 patients were treated with either MMC 
(N=41) or MMC and hyperthermia (N=42)70. The patient group treated with MMC and 
hyperthermia showed significantly fewer recurrences then the group treated with solely MMC 
(17.1% and 57.5%, respectively). Subsequently, a trial focussing on patients with GIII bladder 
tumours treated with either a prophylactic protocol or with an ablative protocol was 
published71. Complete ablation of the tumour was accomplished in 21 patients (75%). After a 
mean follow-up of 20 months, 80.9% of these patients were recurrence free. The results are 
discussed more extensively in the appendix of chapter 8 of this thesis. 
Recently, data of 90 intermediate risk and high risk patients, treated with microwave induced 
hyperthermia and intravesical chemotherapy (1994-2002), were analyzed72. The one and two 
year recurrence rate was 14.3%, respectively 24.6%. The results are discussed in chapter 8 of 
this thesis.  
 
 
Conclusions 
 
Intravesical chemotherapy is an effective treatment for patients with superficial bladder 
cancer. A frequent side effect of all drugs is chemical cystitis in 20-30%, although reversible 
and seldom severe. However, there are differences in other side effects.  
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Adjuvant intravesical chemotherapy has no impact on progression and survival benefit41;73, 
but it does influence the recurrence rate. For example, one immediate single chemotherapeutic 
instillation in patients with a relatively benign type of TCC lowers the recurrence rate in the 
first year with 40-50%. Furthermore, in optimal conditions all chemotherapeutics 
administered in an adjuvant setting to TUR are able to improve recurrence rates with 15 to 
25% for one to three years73. Greater reductions in the 1 to 3 year recurrence rates have been 
suggested by others, which in part might be explained by the study design of the studies 
included in this meta-analysis74. After a median follow-up of eight years, 8% fewer 
recurrences were seen after intravesical chemotherapy73. Of most drugs, different doses and 
schedules are used, without significant impact on results. Finally, for all drugs the advantage 
of maintenance treatment is controversial.  
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Abstract 
 
Hyperthermia combined with chemotherapy is not a novel cancer treatment. However, the 
working mechanism of this combination therapy is not fully understood. The current in vitro 
study investigates the differences in cytotoxicity of four chemotherapeutic agents at 37°C or 
43°C. 
The human transitional cell carcinoma (TCC) cell lines used were RT4, RT112, 253J and 
T24. The cells were seeded in 96-well microtiter plates. After 24 hours cells were treated for 
60 minutes with increasing concentrations of mitomycin-C (MMC), epirubicin, gemcitabine 
and EOquinTM (EO9) at a temperature of 37°C or 43°C. After treatment cells were rinsed 
three times and left for 24 hours in the incubator at 37°C. The influence of chemotherapy and 
temperature on cell survival was determined by an MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazoliumbromide) assay. 
Decreased cell proliferation with increasing concentrations of chemotherapeutic agents was 
demonstrated. EO9 proved to be the most potent agent at both temperatures. Hyperthermia 
alone did not demonstrate   decreased   cell proliferation. However, a synergistic effect on the 
decreased cell proliferation was demonstrated in all cell lines and chemotherapeutic agents 
used, although each with a maximum at a different chemotherapy concentration and to a 
different extent. Synergism was most obvious in cell lines treated with low dose epirubicin.  
Synergism with hyperthermia and chemotherapy was clearly demonstrated for Epirubicin, 
EO9, MMC and, to a lesser extent, gemcitabine. Hyperthermia alone did not cause a 
significant decrease in cell proliferation. Synergism was most prominent with low drug doses, 
and the most potent drug used in this in vitro study was EO9.   
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Introduction 
 
Hyperthermia combined with chemotherapy is not a novel cancer treatment. The first 
experiences date from more than a hundred years ago1. For the treatment of transitional cell 
carcinoma (TCC) of the bladder, thermo-chemotherapy has been studied for nearly forty years 
now and is an encouraging option2,3. Nevertheless, the working mechanism of this 
combination therapy is not fully understood.  
In 1992 Matzkin et al. performed an in vitro study where solely hyperthermia (±43ºC) was 
used in the treatment of superficial TCC of the bladder4. He concluded that the cytotoxic 
effect of hyperthermia in bladder TCC is variable and very limited. Furthermore, he 
concluded that experiments using the combination of hyperthermia and intravesical anticancer 
agents are needed.  
More than ten years later, we have shown that mitomycin-C (MMC) and 43°C-hyperthermia 
induces an increase in cytotoxicity5. In the current in vitro experiment differences in 
cytotoxicity between increasing concentrations MMC, epirubicin, gemcitabine and EOquinTM 
(EO9) combined with 43°C-hyperthermia for 60 minutes (the clinical situation) are studied.  
MMC is frequently used as intravesical chemotherapeutic agent. This potent antibiotic 
antitumour agent interacts with DNA. The cytotoxicity of MMC is a direct result of DNA 
damage6. Epirubicin (4'-epi-doxorubicin) is also a frequently used intravesical 
chemotherapeutic agent. It is an analogue of the anthracycline antibiotic doxorubicin, which 
differs only in the position of the C-4 hydroxy group of the aminosugar moiety. Epirubicin 
binds to DNA and inhibits nucleic acid synthesis and function. Gemcitabine is a novel 
deoxycytidine analogue with a broad spectrum of antitumour activity, including initial results 
when used intravesically. After intracellular activation, the active metabolite is incorporated 
into DNA, resulting in inhibition of further DNA synthesis. The last chemotherapeutic agent 
used in this study is EO9. EO9 is a novel bioreductive alkylating indoloquinone. Although 
structurally related to MMC (figure 1), EO9 exhibits a distinct preclinical antitumour activity 
and there are differences in biochemical activation. The activity of EO9 has been tested in 
several solid tumour cell lines and is presumably related to the presence of DT-diaphorase 
enzyme in the tumour issue7. EO9 is currently under investigation for intravesical use in 
superficial bladder cancer.  
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Figure 1.  Chemical structures of EO9 (left) and MMC (right). Both agents have an identical core 
structure, with different side-chains.  
 
 
Material and methods  
 
Cell lines and culture conditions  
 
The human TCC cell lines used in this study were RT4, RT112, 253J and T24. These TCC 
cell lines display phenotypes associated with well differentiated, moderately differentiated 
and poorly differentiated TCC cells. RT4 and RT112, although originating from invasive 
bladder cancers, behave in vitro in a superficial pattern and are widely used as models of 
superficial bladder cancer8. T24 and 253J are widely used as models of invasive bladder 
cancer9,10. Cell lines were cultured in RPMI 1640 medium (Invitrogen), supplemented with L-
glutamine (Invitrogen), 10% fetal bovine serum (SIGMA-Aldrich), penicillin G (100 U/mL; 
Invitrogen) and streptomycin (100 µg/mL; Invitrogen), at 37ºC in a 5% CO2 humidified 
atmosphere. Cells were fed twice a week with fresh medium and passaged when confluent. 
The human cell lines were passaged using trypsin EDTA (Invitrogen). 
 
 
Thermo-chemotherapy 
 
For treatments, cells were seeded in 96 well microtiter plates at a density of 2.0x104 cells per 
well. Cells were left to attach for 24 hours. Subsequently, all cells were treated with an 
increasing dose of MMC (0-2mM; Christiaens BV, Breda, The Netherlands), epirubicin (0-
2mM; Pharmacia BV, Woerden, The Netherlands), EO9 (0-1mM; Spectrum Pharmaceuticals 
Inc., California, USA), or gemcitabine (0-64mM; Eli Lilly, Houten, The Netherlands).  
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The microtiter plates were placed in a thin layer of water in a 37°C or 43°C incubator. After 
60 minutes treatment cells were rinsed three times with 37°C-culture medium and left for 24 
hours in the incubator at 37°C. 
 
 
MTT assay  
 
The influence of chemotherapy and temperature on cell survival was determined by the MTT 
assay. Twenty-four hours post-treatment, 30 µl MTT solution, 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazoliumbromide (5 mg/ml; SIGMA-Aldrich), was added to the medium. The 
blue dye taken up by the cells after 4 hours incubation was dissolved in DMSO (100 µl/well), 
and its optical density at 595 nm was read on an automated microplate reader (Bio-Rad 3550). 
Studies with the MTT assay showed that the absorption was directly proportional to the 
number of cells. All experiments were done in quadruplicate and repeated at least three times.  
 
 
Calculation of synergism 
 
The equation used to calculate the level of synergy between chemotherapeutic agent and 
hyperthermia-induced cell kill is: 
 
 
          ((100 - % viable cells after hyperthermia + Chemo)-(100 - % viable cells after Chemo))  
ST=60=______________________________________________________________________x 100% 
            (100 - % viable cells after Chemo) 
 
This equation is a method to approximate the synergistic effect after 60 minutes (T=60) 
treatment. 
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Results 
 
The effect of temperature at which chemotherapeutic agents act on different cell lines was 
investigated. Heating to 43ºC for 60 minutes was compared to the exposure at 37ºC. The 
number of cells for each cell line treated with solely hyperthermia was compared with the 
number of cells at 37ºC and was found nearly identical (table 1). Therefore, cell killing by 
hyperthermia alone was excluded, and the number of untreated cells was set to 100 percent.  
The thermo-chemotherapy sensitivity of human bladder cancer cell lines for the four 
chemotherapeutic agents is shown in figure 2-5.  
 
 
Bladder cancer cell line Hyperthermia (43ºC) 
T24 89.9% 
RT112 84.7% 
RT4 86.9% 
253J 86.1% 
 
Table 1.  The percentage of viable cells treated with solely hyperthermia compared to 
the exposure at 37ºC 
 
 
The curves of the cell lines treated with EO9 showed the strongest decrease in cell 
proliferation (figure 2). The LD50 was reached at different values, with a maximum 
concentration of 0.010 mM EO9. The concentration EO9 at LD50 depends on the type of cell 
line and the applied temperature. The effect of hyperthermia on cell lines treated with MMC 
or epirubicin is shown in figure 3 and 4, respectively. The highest synergistic effect of 
hyperthermia is found in the cell lines treated with epirubicin. Nevertheless, most cell lines 
treated with low dose EO9 and MMC showed also a major synergistic effect with 
hyperthermia. The curves of the cell lines treated with gemcitabine showed the least 
synergism (figure 5). The LD50 was reached at a maximum concentration of 25 mM 
gemcitabine. This concentration depends on the type of cell line used and the applied 
temperature.  
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Figure 2.  Effect of one hour hyperthermia (43ºC) and EO9 treatment (black line; triangle) on the 
growth of four human bladder cancer cell lines compared to cells treated one hour with EO9 
at 37°C  (grey line; square).The dotted line indicates the LD50 axis. The vertical axis 
represents the cell survival (scale 0-1) and the horizontal axis represents the concentration 
EO9 in µg/mL.  
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Figure 3.  Effect of one hour hyperthermia (43ºC) and MMC treatment (black line; triangle) on the 
growth of four human bladder cancer cell lines compared to cells treated one hour with MMC
at 37°C  (grey line; square).The dotted line indicates the LD50 axis. The vertical axis 
represents the cell survival (scale 0-1) and the horizontal axis represents the concentration 
MMC in µg/mL.  
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Figure 4.  Effect of one hour hyperthermia (43ºC) and epirubicin treatment (black line; triangle) on the 
growth of four human bladder cancer cell lines compared to cells treated one hour with 
epirubicin at 37°C  (grey line; square).The dotted line indicates the LD50 axis. The vertical 
axis represents the cell survival (scale 0-1) and the horizontal axis represents the 
concentration epirubicin in µg/mL.  
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Figure 5.  Effect of one hour hyperthermia (43ºC) and gemcitabine treatment (black line; triangle) on 
the growth of four human bladder cancer cell lines compared to cells treated one hour with 
gemcitabine at 37°C  (grey line; square).The dotted line indicates the LD50 axis. The vertical 
axis represents the cell survival (scale 0-1) and the horizontal axis represents the 
concentration gemcitabine in mg/mL.  
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The thermo-chemotherapy sensitivity of human transitional cell carcinoma cell lines was not 
uniform. In table 2 the LD50 of all chemotherapeutic agents, used under 37ºC and 43ºC, are 
shown.  
Depending on the type of cell line used, the concentration EO9 to reach LD50 at 37ºC was 6 to 
78 times lower than the concentration MMC. When hyperthermia was given simultaneously 
with EO9, the combined potency increased and the EO9 dose used to reach LD50 decreased by 
21% to 56%. 
 
 
Treatment  LD50 RT112 LD50 T24 LD50 253J LD50 RT4 
MMC  37°C 
MMC  43°C 
∆ LD50 [MMC] 
99 x 10-3 
84 x 10-3 
85% 
210 x 10-3 
36 x 10-3 
17% 
280 x 10-3  
200 x 10-3 
71%  
35 x 10-3 
30 x 10-3 
86% 
EO9  37°C 
EO9  43°C 
∆ LD50 [EO9] 
3.3 x 10-3  
2.6 x 10-3 
79% 
9.9 x 10-3 
5.9 x 10-3 
60% 
3.6 x 10-3  
1.6 x 10-3 
44% 
6.4 x 10-3 
3.0 x 10-3 
47% 
Epirubicin  37°C 
Epirubicin  43°C 
∆ LD50 [epirubicin] 
26 x 10-3 
3.4 x 10-3 
13% 
1827 x 10-3 
95 x 10-3 
5% 
100 x 10-3  
21 x 10-3 
21%  
21 x 10-3 
4.9 x 10-3 
23% 
Gemcitabine 37°C 
Gemcitabine 43°C 
∆ LD50 [gemcitabine] 
21 
14 
67% 
26 
18 
69% 
27 
23 
85%  
23 
18 
78% 
 
Table 2.   The LD50 and ∆ LD50 of all chemotherapeutic agents, used under 37ºC and 43ºC. Calculated by 
the synergism equation, hyperthermia has a synergistic effect on all chemotherapeutic agents. 
In all cell lines such a synergistic effect was shown, although each with a maximum at a 
different chemotherapy concentration and to a different extent. The extend of synergism at 
LD50 for all chemotherapeutic agents and cell lines used are shown in table 3. As shown in this 
table, synergism is most obvious in cell lines treated with epirubicin. 
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Treatment SLD50 RT112 SLD50 T24 SLD50 253J SLD50 RT4 
MMC 43°C 18% 483 % 40% 17% 
EO9 43°C 50% 68% 125% 113% 
Epirubicin 43°C 665% 1823% 376% 329% 
Gemcitabine 43°C 50% 44% 17% 28% 
 
Table 3.  Synergism (in percents) at the level of 50% cell kill (SLD50) is shown for all chemotherapeutic 
agents used.   
 
 
Discussion 
 
Malignant cells have been found to be more sensitive to heat than normal cells or tissues11. 
Matzkin et al. performed an in vitro study on the effect of solely hyperthermia, one hour at 
43ºC, in human bladder cancer cell lines4. This study showed a decline in growth in only one 
out of five cell lines, suggesting that the effect of solely hyperthermia in bladder cancer is 
limited. The results of this in vitro study support these findings. Nevertheless, at temperatures 
above 37°C, the ability to kill malignant cells of many, but not all, anticancer drugs increases 
substantially12. 
Research dealing with intravesical thermo-chemotherapy has focussed on the effect at 42°C to 
44°C. Higher temperatures may be more beneficial, but will also irreversibly damage the 
normal urothelium and bladder wall. The increased cell-killing rate at 42°C to 44°C in 
combination with intravesical chemotherapy can be used in clinical practise. The combination 
of intravesical MMC and hyperthermia has been studied extensively in the treatment of 
superficial bladder cancer2,13,14. A prospective randomized trial in patients with superficial 
bladder cancer showed that the combination of MMC and hyperthermia is more effective than 
the standard intravesical MMC treatment2.  
In the current study the synergistic effect of a single treatment with hyperthermia and four 
different chemotherapeutic agents was studied in vitro. A synergistic effect on the decreased   
cell proliferation was demonstrated in all cell lines and in all chemotherapeutic agents used, 
although each with a maximum at a different chemotherapy concentration and to a different 
extent. The most potent drug was EO9. This novel bioreductive drug has good 
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pharmacodynamic properties in vitro, modest anti-tumour activity in experimental tumour 
models, but failed to show activity in clinical trials when given intravenously15. The reason 
for its poor efficacy in vivo is the suboptimal drug delivery to the tumour site and rapid 
clearance from the blood stream (t½<10 minutes), which must contribute to its rapid 
pharmacokinetic elimination in vivo16 and poor penetration through avascular tissue. This is a 
problem in systemic treatment of cancer, but may be of no relevance in intravesical 
application. In intravesical use the drug delivery is no problem and in case EO9 is absorbed 
systemically, it will be removed very fast. In clinical practise the intravesical dose EO9 is 8 
times lower than the intravesical dose MMC (4mg/40mL EO9 versus 40mg/50mL MMC). In 
the current study the LD50 of EO9 was 6 to 78 times less than MMC, depending on the type of 
cell line used. This makes EO9 a very potent chemotherapeutic agent. Furthermore, under 
hyperthermic conditions the LD50 of EO9 decreased with another 21 to 56%. Mostly, 
synergism was seen in the lower concentrations of EO9. After all, a high drug dose induces 
already maximum cell kill independent of the applied temperature. Despite the huge 
differences between the cell lines, the synergism of epirubicin combined with hyperthermia is 
superior to other chemotherapeutic agents used under hyperthermic conditions. The decrease 
in LD50 of epirubicin under hyperthermic conditions seems more significant, with 329% to 
1823%. 
In the last decade, a limited number of patients were treated with thermo-chemotherapy using 
epirubicin (50mg/50mL). Patients were suffering a lot of local side effects and mostly 
treatment was terminated prematurely. Looking at these in vitro results, probably the dose of 
epirubicin used should have been lower, for example half the normal intravesically applied 
dose of 50mg/50mL. The LD50 of gemcitabine is much higher than the LD50 of the other 
chemotherapeutic agents used. Also, in clinical practise patients receive a substantially higher 
dose gemcitabine than for example MMC (2,000mg/mL gemcitabine versus 40mg/50mL 
MMC). Furthermore, under hyperthermic conditions synergism was limited. This makes 
gemcitabine the least potent agent in this experiment.  
From this in vitro study the following conclusions can be drawn: I. Solely hyperthermia does 
not influence the cell proliferation significantly. II. A synergistic effect on the decreased cell 
proliferation was demonstrated in all cell lines and in all chemotherapeutic agents, with EO9 
and hyperthermia as the most potent combination. III. The extent of synergism was different 
for each drug, but most outspoken for epirubicin. IV. Mostly, synergism was seen in the lower 
drug concentrations.  
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In this experiment, synergism was reported as function of the chemotherapeutic 
concentration, and the type of cell line used. The increased therapeutic effect of hyperthermia 
and a chemotherapeutic agent is in agreement with the synergistic cell killing shown in this 
experiment. One explanation for the increased effect is a higher uptake of the 
chemotherapeutic agent under hyperthermic conditions. Another possibility is that the drug 
becomes more activated and consequently induces more DNA damage. Counterargument for 
the theory of a higher uptake is the fact that this study shows that the decrease in LD50 of 
gemcitabine under hyperthermic conditions is only 17.4% to 50% (Van Bree et al. even 
showed no synergistic cytotoxicity with the use of gemcitabine under similar experimental 
conditions17). Whereas epirubicin, a DNA damaging agent with a much higher molecular 
weight, shows a decrease in LD50 of 329% to 1823% under hyperthermic conditions. 
Apparently, a drug-specific activation under hyperthermic conditions is more likely than an 
increased uptake of the drug.  
The increased cytotoxicity can be explained by a decrease in cell proliferation, an impaired 
cell repair or an increased rate of apoptosis. All these factors can be mediated by the p53 
tumour suppressor protein. In this study wild type p53 cell lines, 253J and RT4, were 
compared with mutant type p53 cell lines, RT112 and T24. It is known that p53 is responsible 
for repair or apoptosis in response to DNA damage18. Since the p53 protein is inactivated at 
temperatures above 41ºC, p53 mediated DNA damage response should be impaired19,20. 
However, in the current study the differences in p53 status did not influence the outcome of 
cell survival after thermo-chemotherapy, suggesting that also DNA damage is not the main 
mechanism of action.  
The working mechanism of thermo-chemotherapy is still not fully understood. These 
observations emphasize that the next phase of in vitro studies with thermo-chemotherapy have 
to focus on the drug-specific activation under hyperthermic conditions. Clinical studies have 
to evaluate whether the combination of an appropriate dose of epirubicin and hyperthermia or 
EO9 and hyperthermia is more effective than the standard thermo-chemotherapy with MMC.  
 
 
Conclusion 
 
A synergistic effect on the decrease of cell proliferation was demonstrated in all cell lines, 
although each with a maximum at a different chemotherapy concentration and to a different 
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extent. The most potent drug used in this in vitro study was EO9. However, under 
hyperthermic conditions the synergism with epirubicin was superior to the use of EO9. 
Nevertheless, the low LD50 combined with the significant synergy makes EO9 the most 
promising agent in this in vitro study.  
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Abstract 
 
Gemcitabine is a deoxycytidine analogue, used intravenously in the treatment of several 
tumours, including transitional cell carcinoma of the bladder. It has been shown to be 
effective and well tolerated when given systemically. We investigated the use of this agent 
administered intravesically in pigs for histological studies of the bladder and pharmacokinetic 
research. 
Two groups of 5 female pigs each received once 175 mg and 350 mg gemcitabine 
intravesically for 2 hours. A third group of 5 pigs received 350 mg gemcitabine weekly for 6 
weeks. Animals were observed for clinical signs of toxicity. Blood was withdrawn for 
gemcitabine pharmacokinetics and in group 3 also for peripheral blood counts. The animals 
were euthanized 24 hours after (the last) instillation. Histological examination of the bladder 
wall was performed. 
Doses of 175 and 350 mg gemcitabine were well tolerated. The animals showed no signs of 
deterioration of their well-being. Peripheral blood counts showed no signs of 
immunosuppression in the third group. In none of the pigs systemic absorption was seen, up 
to 4 hours after the beginning of instillation. Histology showed in all cases normal bladder 
wall histology, except for some cases with mild signs of infection (mainly group 3). 
The use of gemcitabine as an intravesical agent in pigs is well tolerated, has no bladder 
toxicity and is not absorbed systemically.  
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Introduction 
 
Superficial transitional cell carcinoma (TCC) of the bladder has a high and rising incidence 
and an even higher prevalence because of its high recurrence rate after primary transurethral 
resection (TUR). Intravesical instillations are used to lower the recurrence rate and the chance 
of progression to muscle invasive disease. For intravesical instillations the choice is in 
principal twofold: intravesical chemotherapy or intravesical immunotherapy. Intravesical 
chemotherapy reduces the risk of recurrence in the first years after therapy, but this effect 
becomes smaller after a longer period of follow-up. In a large meta-analysis Pawinski et al 
showed that after 5 years of follow-up the treated group only had a 6% lower recurrence rate 
as compared to the none treated group1. Moreover, it has been shown repeatedly that 
intravesical chemotherapy has no influence on progression. Intravesical immunotherapy is 
practically synonymous for intravesical BCG. Of intravesical BCG it is clear that the 
reduction of the recurrence rate after TUR is significantly higher as compared to intravesical 
chemotherapy, although at the cost of more and more severe side effects2. Additionally, recent 
data have shown that BCG can even delay tumour progression3. In all, there seems to be a 
need for new drugs in the treatment of patients with superficial bladder cancer, with higher 
efficacy and/or less toxicity. 
One of these newer drugs is gemcitabine, a novel deoxycytidine analogue. Gemcitabine has 
been used in several tumours, and it has been shown to be effective and well tolerated when 
given systemically. In advanced bladder cancer patients gemcitabine appears to be one of the 
most effective drugs available. To test the potential and risks of gemcitabine when used 
intravesically, we designed an (pharmacokinetic) animal experiment in which we used 
different dosages and schedules of gemcitabine intravesically. To mimic the penetration of a 
nucleoside analogue into the bladder wall, BrdUrd, a thymidine analogue that can be 
visualized with a monoclonal antibody, was instilled into the bladder together with 
gemcitabine. 
 
 
Material and Methods 
 
Approval was granted from the Committee for Animal Experiments (Catholic University of 
Nijmegen, The Netherlands) before the study was undertaken. Female pigs were used for this 
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study, because the urogenital tract of the pig closely resembles the human urogenital system4. 
Nevertheless, male pigs were not suitable because the shape of the penis and the preputial 
diverticulum make it impossible to catheterize transurethrally. The pigs were divided in 3 
groups of 5 F2 pigs (F2 pigs are obtained by crossing a York male pig and a F1 female pig; 
the F1 pig is a cross-breeding between an English pig and a Large White pig). The pigs were 
housed in special swine stainless steel battery cages and fed with universal swine food 
(Hendrix UTD B.V., Boxmeer, The Netherlands). The first two groups received one 
intravesical instillation with 175 mg and 350 mg gemcitabine (provided by Lilly, Houten, the 
Netherlands) in 50 cc 0.9% (10 French Foley catheter). In the same instillation 10 mg 5-
Bromo-2’-deoxyuridine (BrdUrd, Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) was dissolved. The catheter was clamped and the instillation was maintained 
into the bladder for 2 hours, after which the bladder was emptied. Blood samples were taken 
for pharmacokinetics by puncturing the jugular groove, near the manubrium. In this way 
blood was collected from the cephalic vein, the internal or external or communal jugular vein 
depending on the puncture site, angle and depth. In these first two groups blood was taken 
before instillation of gemcitabine, 30, 60 and 120 minutes after the start of instillation, and 
again 15, 30, 60 and 120 minutes after emptying of the bladder. Blood samples for 
gemcitabine measurement were drawn in tubes, to which 10 µl of THU (1 mg 
tetrahydrouridine/ml phosphate buffered saline; Calbiochem, San Diego, CA, USA) were 
added to prevent ex vivo degradation of gemcitabine by cytidine deaminase in the serum. The 
whole procedure was done under general anaesthesia. For premedication one shot azaperon (4 
mg/kg) i.m. was used. Sedation was induced with a mixture of midazolam 0.45 mg/kg i.v. and 
atropine 0.045 mg/kg i.v. and maintained with a mixture of ketamine 10 mg/kg/h i.v. and 
midazolam 0.35 mg/kg/h i.v. The well being of the animals was observed by experienced staff 
after the procedure and 24 hours after the instillation the animals were euthanized and 
cystectomized and the bladder was investigated histologically. The third group received 350 
mg gemcitabine intravesically in 50 cc 0.9% saline weekly for 6 weeks. The conditions were 
the same as in the first two groups. The procedure was also done under general anaesthesia. 
The instillation was left in place for two hours, but blood was only withdrawn 60 minutes 
after instillation, again for measurement of gemcitabine, white blood cell and thrombocyt 
count. Animals were observed for clinical signs of toxicity. The animals were euthanized 24 
hours after the last instillation; histological examination of the bladder wall was performed. 
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Pharmacokinetics 
 
In order to evaluate the systemic absorption of gemcitabine before, during and after the 
administration of intravesical gemcitabine, blood samples were collected in heparinised tubes 
and in CPT-tubes (Cell Preparation Tube with Sodium Citrate, Becton Dickinson Vacutainer 
Systems, Alphen aan den Rijn, The Netherlands).  
After blood sample collection the heparine-tubes (each containing 10 µl of THU (1 mg 
tetrahydrouridine/ml phosphate buffered saline) were inverted to mix the blood, with the 
anticoagulant and the THU. Thereafter, the tubes were immediately placed on ice and 
transferred to the lab for preparation. Centrifugation of the tubes took place for 5 minutes at 
4000 rpm at 4°C. The top layer (plasma) was transferred with a pipette into another tube. 
These tubes were frozen, stored at -20°C, and further processed in Amsterdam. The CPT-
tubes were inverted after blood collection to mix the anticoagulant additive with blood (these 
tubes do not contain THU). The tubes were stored at room temperature until centrifugation. 
The blood samples were remixed immediately prior to centrifugation by gently inverting the 
tube and then centrifuged for 30 minutes at 3200 rpm at normal room temperature. After 
centrifugation the whitish layer just under the plasma layer was collected with a pipette 
together with the plasma layer to be transferred to a new tube. The procedure was repeated 
and again the two above-mentioned layers were transferred to a new tube. To this tube PBS 
(4°C) was added to a volume of 10 ml. 20 µl were used to count the cells with a counting 
chamber. The rest was centrifuged for 25 minutes at 2500 rpm at 4°C. As much supernatant as 
possible was aspirated without disturbing the cell pellet and the cell pellet was transferred to a 
1,5 ml Safelock tube. Again centrifugation took place for 5 minutes at 13000 rpm at 4°C. The 
supernatant was removed and the cell pellet immediately frozen in liquid nitrogen and stored 
at -80°C until analysis of nucleotides and 2’2’-difluoro-2’deoxycytidine-triphosphate 
(dFdCTP), the active metabolite of gemcitabine. 
All samples were sent as one batch to the VU University Medical Centre in Amsterdam, The 
Netherlands. Plasma levels of gemcitabine and its metabolite 2’2’-difluorodeoxyuridine 
(dFdU) were measured with a validated ion-pair reversed-phase HPLC assay using an Aqua 
column (150 x 4.6 mm, 3 µm) (Phenomenex, Bester, Amstelveen, The Netherlands) as 
described previously5. The concentrations of normal nucleotides and of dFdCTP in white 
blood cells were measured using a validated anion-exchange HPLC method using a Partisil 
SAX column (110 mm x 4.6 mm, 5 µm) (Whatman, Bester Amstelveen, the Netherlands) as 
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described previously5. Blood samples for leukocytes and thrombocyte measurement were 
collected in K3E 15% tubes and sent to our clinical chemical laboratories for determination of 
levels. 
 
 
Results 
 
One instillation of 175 and 350 mg gemcitabine was well tolerated, as well as the course of 6 
weekly instillations with 350 mg gemcitabine. The animals showed no signs of deterioration 
of their well-being. Pharmacokinetic studies showed that both gemcitabine and its metabolite 
dFdU were not measurable in plasma, both in samples collected at the single administration 
and in samples collected after repeated administration. Since the active metabolite of 
gemcitabine, dFdCTP might accumulate in white blood cells even after discontinuation of the 
instillation, we also evaluated whether this metabolite would be measurable in white blood 
cells. However, in none of the white blood cells dFdCTP was measurable. Since we observed 
previously5,6 that gemcitabine can have profound effects on normal nucleotide pools we also 
evaluated whether the concentrations of normal nucleotides and their ratios was affected by 
gemcitabine instillation. E.g. the ratio CTP/UTP was related to the efficacy of gemcitabine in 
a cell line6. However, both the ATP/ADP ratio and that of CTP/UTP did not 
change during instillation and their ratios were comparable to that published previously7. 
These data demonstrate that in healthy pigs systemic absorption of gemcitabine would be 
negligible at least during the 4 hours after beginning of instillation.  
In group 3 peripheral blood counts displayed no signs of immunosuppression (figures 1 and 
2). Both leukocyte counts and erythrocyte counts remained within the normal range. 
The resected bladder showed no macroscopic abnormalities such as oedema or erosions. 
Histology of the bladder wall showed in all cases normal bladder histology, without mucosal 
atypia and detrusor changes. Only in some cases mild signs of inflammatory response 
(subepithelial leukocyte infiltration) and epithelial cellular and nuclear enlargement were 
seen, mainly in group 3 after 6 instillations (figures 3-5). 
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Figure 1:  White blood cell count in 5 pigs during 6 weekly instillations 
 
 
 
 
Figure 2:  Red blood cell count in 5 pigs during 6 weekly instillations 
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Figure 3: Histological appearance of a normal pig bladder. 
 
Figure 4:  Pigs bladder after one instillation with 350 mg gemcitabine in 50cc 0.9% NaCl. Slight 
thickening of the urothelial layer can be seen. 
 
Figure 5:  Pigs bladder after 6 instillations with 350 mg gemcitabine in 50cc 0.9% NaCl. Subepithelial 
leukocyte infiltration as can be seen in case of infection (left). Thickening of the urothelial 
layer can be seen, with some cellular and nuclear enlargement (right). 
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Discussion 
 
As pointed out in the introduction, there are several arguments to look for new drugs for 
intravesical use in case of superficial bladder cancer. Currently used chemotherapeutic drugs 
are very safe, but lack significant prevention of recurrences on the long run, and have no 
impact on progression to muscle invasive disease. Intravesical BCG, on the other hand, is 
more effective in reducing the recurrence rate, even seems to reduce progression, but is 
significantly more toxic, with even deaths having been described. 
Gemcitabine (2’,2’-difluorodeoxycytidine, dFdC) is transported into the cell and 
phosphorylated (dFdC-triphosphate, dFdCTP) prior to incorporation into DNA and RNA, 
which causes inhibition of growth activity and mediates apoptosis8. Gemcitabine is 
deactivated by deamination into 2’,2’-difluorodeoxyuridine (dFdU) and transported out of the 
cell. Gemcitabine was first screened for antiviral activity in the eighties, but appeared to have 
remarkable activity in solid tumours, such as ovarian and non small-cell lung cancer. The first 
preliminary report on the use of gemcitabine in advanced bladder cancer was published in 
19949. In subsequent single agent trials promising response rates and acceptable toxicity were 
reported, even as second line10-12. After these single-agent studies several phase II reports 
were published combining gemcitabine with other drugs, again with mild toxicity, good 
tolerance and promising response rates between 54 and 68%13-17. Finally, a large phase III 
study in 405 patients with locally advanced or metastatic TCC compared gemcitabine and 
cisplatin (GC) versus methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)18. The 
results suggest a better safety profile and tolerability of GC, and similar survival advantage, 
although the trial was not designed as an equivalence trial.  
Gemcitabine has several features that make it an attractive alternative chemotherapeutic agent 
for intravesical use in patients with TCC. As has been explained above, the single-agent 
activity against TCC is significant. The molecular weight of gemcitabine (299,66) is high 
enough to assume there will be no systemic absorption. Furthermore, the systemic toxicity 
profile is mild, so in case of systemic absorption the consequences would be minimal. 
Two phase I studies with intravesical gemcitabine have been published to date19,20. Both 
studies conclude that gemcitabine has substantial activity, even in BCG refractory patients. 
Local side effects are minimal, systemic side effects minimal in case of one instillation 
weekly, tolerable in case of a twice-weekly instillation schedule. One other animal study has 
been reported with intravesical gemcitabine21. Cozzi et al. used intravesical gemcitabine in 
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beagle dogs.  Three groups of 2 dogs received 100 mg, 350 mg (equivalent to the 1000 mg/m2 
human dose) and 1000 mg gemcitabine in 50 ml normal saline intravesically, three times one 
hour weekly for 4 weeks. Two dogs also received 350 mg intravenously over a 1 hour period. 
Animals were observed clinically, and blood samples for pharmacokinetics and peripheral 
blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy 
was performed at days 1 and 14 after the last dose. Both 100 mg and 350 mg intravesically 
were tolerated without clinical signs of side effects. With the 350 mg dose a slight drop in 
platelet and white cell count was seen towards the end of the 4-week treatment period (12 
instillations) with quick recovery after cessation of therapy. At necropsy no toxic effects were 
observed, in particular not in the bladder or bone marrow. Initially two dogs were treated with 
350 and 3500 mg intravesically, and two additional study dogs were treated with 1000 mg. 
Both the 1000 mg as well as the 3500 mg dose caused severe problems: clinical toxicity, 
myelosuppression, high serum levels of gemcitabine and multi-organ toxicity on necropsy. In 
all doses gemcitabine could be measured in serum, with lower serum levels corresponding 
with lower intravesical concentrations. The serum level after the intravesical use of 350 mg 
(approximately 30 µM) was significantly lower than the serum level after intravenous 
administration of a similar dose (approximately 80 µM), similar to concentrations observed at 
high doses gemcitabine in humans5. However, serum levels after intravesical use were 
measurable up to 8 hours after administration, corresponding with a significant longer half life 
time of 328 minutes as compared to 99 minutes after intravenous use, both in the 350 mg dose 
(p<0.001). The authors concluded that, although all doses of gemcitabine were absorbed 
systemically, it was possible to deliver a clinically active dose without bladder or systemic 
toxicity. Our results in pigs support part of the results found in dogs. We also did not find any 
problems with the animals well being, bladder toxicity or systemic toxicity. A major 
difference, however, is the fact that in our pig model no systemic absorption of gemcitabine 
could be measured. This can be explained by the differences in instillation schedules. Our 
instillation schedule (once weekly) was much less frequent than in the dog study (3 times 
weekly), although instillation time was 2 hours as compared to 1 hour in the dog study. It is 
well known that intravesical chemotherapy causes some chemical cystitis with hyperaemia. 
Twelve instillations within three weeks might therefore, very well result in drug absorption, 
especially since this was seen mostly towards the end of the instillation schedule. The 
difference in animal size (pigs are bigger) with the same absolute dose in both studies does 
not seem to be relevant.  
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From a theoretical point of view, gemcitabine is worth investigating for the use in superficial 
bladder cancer. In our animal experiment it was safe in all aspects studied, without systemic 
absorption. A subsequent phase I human study, studying 1000, 1500 and 2000 mg 
gemcitabine in 50 ml saline for intravesical use, will be discussed in chapter 6 of this thesis. 
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Abstract 
 
To study the influence of microwave induced thermotherapy, intravesical chemotherapy or 
the combination of both modalities on high grade urothelial cell carcinomas visualized by 
immunohistochemical staining. 
Five groups of each three patients were formed of whom initial biopsies and cystectomy 
tumour tissue samples were collected. Group 1 patients were treated two days prior to 
cystectomy with solely mitomycin-C (MMC); group 2 patients were treated two days prior to 
cystectomy with solely hyperthermia; group 3 patients were treated two days prior to 
cystectomy with thermo-chemotherapy; group 4 patients had been treated the last 3 months 
before cystectomy with a cycle of six thermo-chemotherapy treatments and group 5 patients 
served as control (no treatment). All tumour samples were stained with Haematoxylin and 
Eosin, monoclonal antibody Ki-67 and the monoclonal antibody p53. 
In six out of the nine patients treated with hyperthermia a decrease in proliferation activity in 
the tumour tissue sample was found. In the MMC group and control group one patient showed 
a decrease, two showed an increase and two showed no difference in proliferation activity. As 
regards p53, seven out of nine patients treated with hyperthermia showed a decrease in p53 
activity. In one patient the tumour was negative for p53. The control group and the group 
treated with MMC did not show any differences concerning p53. The intensity of 
inflammation and haemorrhage did not change compared to the MMC group and control 
group.  
A decrease in proliferation activity and p53 activity illustrate the potential role of thermo-
chemotherapy as a promising intravesical treatment. The absence of induction of 
inflammation and haemorrhage show that the treatment is safe. 
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Introduction 
 
Bladder cancer is the 7th most common cancer worldwide, accounting for 3.2% of all cancers. 
In 2000 an estimated 260,000 new cases in men and 76,000 in women were found 
worldwide1. The highest incidence rates of bladder cancer in both sexes are observed in 
Europe, North America and Australia2. Bladder cancer incidence is still rising moderately in 
most developed countries. Of all these malignant bladder tumours, more than 90% are 
transitional cell carcinomas of which two third is superficial and one third is muscle invasive. 
The management of these two types of transitional cell carcinoma differs enormously. The 
management of superficial bladder cancer consists of transurethral resection in the first place, 
whereas the primary treatment for muscle invasive bladder cancer consists of cystectomy, a 
completely different approach.  
After transurethral resection of a superficial bladder tumour 30 to 85% of patients develop 
recurrences, despite the most accurate resection technique. This high risk of recurrences 
makes bladder cancer one of the most prevalent human tumours. To decrease the number of 
recurrences after transurethral resection, patients are treated subsequently with 
chemotherapeutic or immunotherapeutic agents. Immunotherapy, usually BCG treatment, is 
more effective than any intravesical chemotherapeutic agent, but has more serious and more 
frequent side effects. So, there is a need for more effective treatment options or treatment 
options with less frequent and less severe side effects. A new treatment option in patients with 
intermediate to high risk tumours is the combination of intravesical hyperthermia and 
intravesical chemotherapy3-5.  
The endocavitary location and ease of accessibility by the urethra makes thermo-
chemotherapy a good therapeutic option for superficial bladder cancer. Local hyperthermia at 
temperatures of 40°C to 44°C in combination with selected cytostatic agents in several 
tumours, including transitional cell carcinoma, results in a synergistic anti-tumour effect6. 
In this descriptive study the influence of different treatment modalities on bladder tumours 
(thermo-chemotherapy, chemotherapy and thermotherapy) was investigated by several 
immunohistochemical stainings.  
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Methods 
 
Subjects 
 
The study included 15 patients with high grade transitional cell carcinoma of the bladder. All 
patients signed a patient informed consent and all these patients were facing cystectomy. The 
15 patients were divided in five groups with each three patients. Group 1 patients were treated 
two days before cystectomy with an intravesical mitomycin-C (MMC) instillation.  After the 
bladder was emptied, 20 mg MMC (Kyowa Hakko Kogyo Co., Tokyo, Japan) in 50 mL saline 
was instilled. In order to stabilize the MMC concentration in the bladder throughout the entire 
session, the bladder was emptied after 30 minutes and the with urine diluted solution was 
replaced by a new solution containing 20 mg MMC. Group 2 patients were treated two days 
before cystectomy with sterile water and local hyperthermia. To standardize treatments the 
instillation was replaced after 30 minutes. The local microwave induced hyperthermia was 
delivered by the SB-TS 101 system as described by Colombo et al7. This system consists of a 
915 Mhz. intravesical microwave applicator that delivers hyperthermia of the bladder walls 
via direct irradiation. The applicator is part of the specially designed 20F transurethral 
catheter. The catheter also contains 5 thermocouples. Two thermocouples measure the 
temperature in the prostatic urethral tract; the other three are spread out and pushed 
tangentially against the posterior and lateral walls of the bladder. To avoid urethral 
overheating, the solution is continuously pumped out of the bladder and re-instilled after 
being cooled. Hyperthermia was delivered within a temperature range of 41 to 42 degrees 
Celsius. 
Group 3 patients were treated two days before cystectomy with two times 30 minutes 
intravesical MMC (20mg in 50mL sterile water) combined with local microwave induced 
hyperthermia delivered by the SB-TS 101 system. Group 4 patients were treated with a cycle 
of six thermo-chemotherapy treatments during the last three months. Finally, group 5 patients 
served as control group. These patients did not receive any intravesical instillations within 3 
months prior to cystectomy. 
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Immunohistochemistry 
 
All tumour tissue samples were fixed in a 10% buffered formaldehyde solution. The 
specimens were embedded in paraffin blocks and sections of 4 µm were cut. All specimens 
were deparaffinized and stained with Haematoxylin and Eosin. A microscopic examination of 
the samples was performed and the extend of inflammation (1+ to 3+) and the extend of 
haemorrhage (1+ to 3+) were semi quantitatively scored.  
Ki-67, a nuclear protein present during phases GI, S, GII and M of cycling cells, is accepted 
as a good indicator of cell proliferation8. Sections were deparaffinized and immersed in a 10 
mM sodium citrate buffer (pH 6.0) in a microwave oven for 2 times 5 minutes to enhance 
antigen retrieval. After washing, the slides were incubated with 0.3% H2O2 in methanol to 
quench endogenous peroxidase activity. After incubation at room temperature for 2 hours 
with the anti-Ki67 monoclonal antibody clone MIB-1 (BioGenex) diluted 1:30, a biotinylated 
antibody that recognises murine IgG (BioGenex) was applied for 20 minutes, followed by 
incubation in streptavidin-peroxidase complex (BioGenex) for 20 minutes. The peroxidase 
reaction was developed using 0.5 mg/mL diaminobenzidine tetrahydrochloride (Sigma) in 
0.01% H2O2. Haematoxylin was used as a light counter stain. The slides were dehydrated and 
mounted with a xylene-soluble mounting medium. 
The mutated p53 tumour suppressor gene product can be detected immunohistochemically 
and is associated with a lower survival in patients with bladder cancer 9. Sections were 
deparaffinized and immersed in a 10 mM sodium citrate buffer (pH 6.0) in a microwave oven 
for 2 times 5 minutes to enhance antigen retrieval. After cooling down, 0.6% H2O2 in a 40% 
methanol solution was used for 30 minutes to block endogenous peroxidase activity. Slides 
were pre-treated with 10% normal swine serum for 10 minutes to block non-specific staining 
followed by adding primary antibody DO-7 for 1 hour at 20 degrees Celsius. After extensive 
rinsing, sections were incubated for 30 minutes with biotinylated swine anti mouse antibody 
(1:200 dilution) and then for 30 minutes with avidin-biotin complexes (1:50 dilution) at 20 
degrees Celsius. Diaminobenzidine (DAB) staining were finally followed by haematoxylin 
nuclear counter staining. The slides were dehydrated and mounted with a xylene-soluble 
mounting medium. 
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Immunoreactivity scoring 
 
The screening of tumour tissue samples was performed by two independent investigators (CH 
and AH). The sections were screened for positive cells, defined as cells with nuclear staining. 
The amount of proliferation or p53 staining is scored in percentages.  
 
 
Results 
 
15 patients (11 males, 4 females) signed a patient informed consent and participated in this 
study. Ages ranged from 42 to 75 years (mean 63.2 years). All patients underwent cystectomy 
for transitional cell carcinoma of the bladder. Eight patients had a de novo invasive bladder 
tumour, whereas 7 patients had a history of high risk superficial disease. Patient details are 
summarized in table 1.  
 
Groups Patient 
no./age/sex 
N previous 
occurrences 
Interval biopsy 
- cystectomy 
(in months) 
Histopathology 
initial biopsy 
Histopathology 
cystectomy 
1/75/M 0 2,0 ≥pT2aGIII pT3aGIIIN2 
2/46/F 0 4,4 pT2GII pT3bGIIIN1 
1. MMC 
3/67/F 0 1,2 ≥pT2GIII ≥pT2GIII  
4/64/F 0 1,9 pT1GIII pT2aGIII 
5/71/M 3 38,7 pT1GIII + CIS pT1GIII + CIS 
2. HT 
6/42/M 10 121,9 pTaGII pTaGII 
7/55/M 0 2,6 pT1GIII ≥pT2GIII 3. MMC + HT 
8/67/M 0 1,9 pT2GIII pT3aGIIIN1 
 9/48/F 1 3,3 pT1GII pT2bGIIIN1 
10/54/M 18 107,5 pTaGII pTaGII 4. History of MMC + HT 
11/73/M 2 22,3 CIS pT4aGIIIN2 
 12/75/M 10 57,7 pTaGII pTaGII 
13/71/M 9 115,5 CIS pT2GIII 
14/71/M 0 3,1 pT2GIII pT2GIII 
5. Control 
15/71/M 0 3,3 pT2GIII pT2GIIIN1 
 
Table 1.  Patient details containing number of previous occurrences, interval period between initial 
diagnosis and cystectomy in months, pathology data of biopsy and cystectomy (grading 
according to WHO 2002). 
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The initial biopsies and tumour tissues obtained with cystectomy were used for 
histopathological diagnosis and immunohistochemical analysis of Ki-67 and p53. The results 
from the different treatment groups are summarized in table 2. In one patient of the MMC 
group no residual tumour could be retrieved in the cystectomy specimen. The proliferation 
activity and p53 activity could not be scored in that patient.  
The intensity of inflammation increased in three out of nine patients treated with 
hyperthermia. In three out of five patients from the MMC group and control group an increase 
was seen. The intensity of haemorrhage increased in four out of nine patients treated with 
hyperthermia, one patient showed a decrease and four patients did not show any difference. In 
the MMC group and in the control group two patients showed an increase, one patient a 
decrease and two patients did not show any difference. 
In six out of the nine patients treated with hyperthermia a decrease in proliferation activity in 
the tumour tissue sample was found. In the MMC group one patient showed a decrease and 
one showed an increase in proliferation activity. In the control group two out of three patients 
showed no changes, whereas in one patient an increase in proliferation activity was seen. 
As regards p53, seven out of nine patients treated with hyperthermia showed a decrease in 
p53 activity. In one patient no change was found. The control group and the group treated 
with MMC did not show any differences concerning p53.  
 
 
Discussion 
 
Thermo-chemotherapy has shown to be a promising method for treating several kinds of 
malignant tumours including superficial bladder cancer3. While hyperthermia is important in 
cancer therapy, it can also damage normal tissues adjacent to the tumour. Fajardo et al. 
reviewed the effects of hyperthermia from several studies on various tissues of mammals and 
humans6. Hyperthermia with a maximum applied temperature of 44.5 degrees Celsius showed 
no gross or microscopic alterations of the bladder of dogs and rabbits. Subsequently, Rath-
Wolfson et al. studied the effect of hyperthermia, with a maximum applied temperature of 46 
degrees Celsius, and simultaneous MMC treatment in sheep10. In this study thermo-
chemotherapy showed no significant macroscopic or microscopic differences in the bladder 
wall as compared to a control group with untreated sheep.  
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Groups Material Inflammation Proliferation P53 Haemorrhage 
. MMC      
a. biopsy +++ 30% 20% + 
 cystectomy +++ 75% 20% ++ 
b. biopsy ++ 20% 75% - 
 cystectomy +++ 15% 75% + 
c. biopsy +++ 40% 75% +++ 
 cystectomy NA NA NA NA 
2. HT      
a. biopsy + 60% 80% - 
 cystectomy +++ 20% 40% ++ 
b. biopsy + 30% 90% - 
 cystectomy ++ 20% 40% - 
c. biopsy + 10% - - 
 cystectomy ++ 10% - + 
3. MMC + HT      
a. biopsy +++ 40% >75% - 
 cystectomy +++ 25% 75% - 
b. biopsy +++ >75% >75% + 
 cystectomy +++ 60% 15% - 
c. biopsy +++ 30% >75% + 
 cystectomy +++ 15% 75% ++ 
4. History of  MMC + HT       
a. biopsy + 10% 75% - 
 cystectomy + 20% - - 
b. biopsy +++ 30% 25% - 
 cystectomy +++ 30% 25% - 
c. biopsy ++ 50% 20% - 
 cystectomy ++ 20% 10% + 
5. Control       
a. biopsy + 15% >75% - 
 cystectomy +++ 40% >75% - 
b. biopsy ++ 40% 20% - 
 cystectomy ++ 40% 20% - 
c. biopsy ++ 35% 75% + 
 cystectomy +++ 35% 75% - 
 
Table 2.   The p53 and Ki67 immunoreactivity scorings in percentages of all patients divided in five 
different treatment groups. The extend of inflammation and haemorrhage is semi quantitatively 
scored (1+ to 3+). NA = not applicable due to absence of residual tumour.  
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In the current study the effect of the combination thermo-chemotherapy is compared with 
solely hyperthermia, solely chemotherapy and no treatment (control group) in human patients 
with high grade urothelial cell carcinoma of the bladder. The system SB-TS 101 used to 
deliver local microwave induced hyperthermia makes it possible to dose the hyperthermia 
very precisely11. In this study hyperthermia was delivered within a temperature range of 41 to 
42 degrees Celsius, the clinical situation. This makes comparison between the different 
groups more accurate.  
The sample size of the group studied is small due to the fact that recruitment of patients was 
difficult. Patients had to agree on an extra treatment session only two days before cystectomy 
which did not give them any benefit at all.  
The degree of inflammation increased in the group treated with solely hyperthermia (N=3), 
solely MMC (N=1) and the control group (N=2). In the group treated with thermo-
chemotherapy two days before surgery the degree of inflammation was initially already 
maximal. In the group treated with a cycle of six thermo-chemotherapy treatments during the 
last three months the degree of inflammation apparently had returned to baseline again.  
At least one patient per group (except the control group) showed an increase in the degree of 
haemorrhage. Patients from group 1 (solely MMC) showed the highest degree of 
haemorrhage.  
Group 3 patients (treated with thermo-chemotherapy prior to cystectomy) show in one patient 
an increase, in one patient a decrease and in one patient a stable extend of haemorrhage. This 
is in line with the results from Rath-Wolfson et al10. Nevertheless, since solely MMC and 
solely hyperthermia gives an increase in haemorrhage, it would have been logical to find a 
higher extend of haemorrhage after the combination of both treatments. Possibly, this is not 
found due to the small sample size.  
The inhibition of proliferation activity is one of the most important goals in cancer treatment.  
All groups treated with hyperthermia showed to a different extend a decrease in proliferation 
activity. Most interesting are the three patients treated with thermo-chemotherapy preceding 
transurethral resection. All three patients showed a decrease in proliferation activity. The 
control group on the other hand shows in two patients no difference and in one patient an 
increase in proliferation activity. In earlier in vitro studies using hyperthermia and bladder 
cancer cell lines, this decrease in cell proliferation due to hyperthermia combined with 
chemotherapeutic agents was already shown12,13. However, in these in vitro studies solely 
hyperthermia did not cause a significant decrease in cell proliferation. Nevertheless, there is a 
 82 
The influence of thermo-chemotherapy on bladder tumours – An immunohistochemical analysis  
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
difference between in vitro and in vivo studies. This in vivo study is the first one showing a 
decreased proliferation activity in humans treated with microwave induced hyperthermia with 
or without MMC. The effect of hyperthermia was seen in six out of nine patients treated with 
hyperthermia preceding transurethral resection. 
 Furthermore, the group treated with solely MMC did not show a significant decrease in 
proliferation activity. This is probably due to the limited penetration properties of this 
intravesically used drug, especially after one single treatment. 
P53 is known to be responsible for repair or apoptosis in response to DNA damage. The p53 
activity, in other words the expression of mutant p53, decreased exclusively in patients treated 
with hyperthermia with or without MMC.  
Previous experiments showed that the p53 pathway is heat sensitive and that the p53 protein is 
inactivated at temperatures above 41 degrees Celsius14,15. When cells were heated to 42.5 
degrees Celsius and returned to normal temperatures, a strong p53 response with an increase 
in protein levels was observed. In our study we found the opposite, but the time interval 
between treatment and cystectomy was, with two days (group 3) and several months (group 
4), significantly longer than the time interval used by Guan et al. Furthermore, the results of 
this study are based on a small number of patients which makes statistic analysis unreliable. 
On the other hand, the current results suggest that thermo-chemotherapy could be an effective 
treatment in patients with a p53 tumour suppressor gene mutated tumour. In all, the results 
show several trends and encourage carrying out larger experimental studies.  
 
 
Conclusion 
 
The degree of inflammation and haemorrhage in bladder tumours did not increase in patients 
treated with hyperthermia. This, in combination with a decrease in proliferation activity and a 
decrease in p53 activity, implies that thermo-chemotherapy is a safe and promising treatment. 
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Abstract 
 
Superficial bladder cancer can be treated by transurethral resection and additional intravesical 
therapy. Although agents like Mitomycin-C, epirubicin and BCG are routinely used, there is a 
need for more potent and/or less toxic agents. Gemcitabine is a deoxycytidine analogue, used 
systemically for several tumours, such as non-localised bladder cancer, where it is effective 
and well tolerated. We investigated the use of three dose levels of gemcitabine when given 
intravesically in humans for safety and pharmacokinetic research. 
Patients with superficial bladder cancer, except pT1GIII or CIS were included. Six weekly 
instillations of 1000, 1500 or 2000 mg gemcitabine were given in 50 mL saline for one hour. 
Dose modifications were defined in case of dose limiting toxicities. Blood samples were taken 
before, and 5, 30, 60 (=evacuation) and 120 minutes after instillations 1, 3 and 6. Samples 
were used for blood counts and pharmacokinetics. Side effects were noted. 
Three, 4 and 3 patients were treated with 1000, 1500, and 2000 mg gemcitabine respectively, 
of which 2, 3 and 1 patient had highly recurrent tumours before treatment. Seven patients 
experienced side effects: two with dysuria after the first instillation, two after instillations 3-6 
and 4-6 and in three patients headache, fatigue and heavy legs were experienced once. All 
side effects were reversible, non-limiting and WHO 1. No macroscopic haematuria was seen. 
Haematology showed only one case of drop in white blood cell count (lowest dose level, after 
the first instillation). Gemcitabine plasma levels were immeasurable or low, with peak levels 
between 30 and 60 minutes, decreasing after more instillations. The metabolite 
difluorodeoxyuridine reached levels of at most 5 µM, indicating a very low passage of the 
drug to the systemic circulation.  
Intravesical gemcitabine in the dose used has minimal and reversible side effects. Plasma 
evaluation indicates that its intravesical use is safe. 
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Introduction 
 
For intravesical instillation after transurethral resection (TUR) of superficial transitional cell 
carcinoma (TCC) of the bladder, the choice is between intravesical chemotherapy and 
intravesical immunotherapy.  
Intravesical chemotherapy is a well-established form of therapy. The side effects are limited, 
except for potential systemic problems after ThioTEPA, due to its low molecular weight. The 
efficacy of intravesical chemotherapy in low and intermediate risk patients is also well 
documented. In low risk patients one immediate instillation after TUR is able to lower the 
relative recurrence rate in the next one to two years with up to 50%1,2. With longer follow-up 
and in optimal conditions a course of intravesical chemotherapy after complete TUR is able to 
improve recurrence rates with 15 to 25% for one to three years3. Others have suggested 
greater reductions in the 1- to 3-year recurrence rates, which in part might be explained by the 
study design of the studies included in this meta-analysis4. However, this difference becomes 
smaller after a longer period of follow-up, as was for example shown in two large meta-
analyses, where after 5 and 8 years of follow-up the treated group only had a 6% and 8% 
lower recurrence rate as compared to the none treated group respectively4,5. Lamm, in an 
earlier analysis, even found no difference with longer follow-up6. The difference between 
these studies might be the drugs used in the study periods, although commonly, drugs used for 
intravesical chemotherapy are considered equally effective. Intravesical immunotherapy is 
practically synonymous for intravesical BCG. Of intravesical BCG it is clear that the 
reduction of the recurrence rate after TUR is significantly higher as compared to intravesical 
chemotherapy, although at the cost of more and more severe side effects7. Additionally, recent 
data have shown that BCG can even delay tumour progression8. However, this is achieved 
with maintenance BCG, with subsequent more toxicity.  
In all, there seems to be a need for new drugs in the treatment of patients with superficial 
bladder cancer, with higher efficacy and/or less toxicity. One of these newer drugs is 
gemcitabine that has been used in several tumours, including TCC. Gemcitabine (2’,2’-
difluorodeoxycytidine, dFdC), a novel deoxycytidine analogue, is transported into the cell, 
phosphorylated (dFdC-triphosphate, dFdCTP) and incorporated into DNA and RNA, which 
causes inhibition of growth activity and mediates apoptosis9. Gemcitabine is deactivated by 
deamination into 2’, 2’-difluorodeoxyuridine (dFdU) and transported out of the cell. It has 
been shown to be effective and well tolerated when given systemically, and in TCC 
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gemcitabine appears to be one of the most effective drugs available. The intravesical 
instillation of gemcitabine has been tested in two animal models 10,11 and in two phase I 
trials12,13. In all four studies it was concluded that local and systemic side effects were 
minimal, and systemic absorption, although dependent on the instillation schedule used, was 
absent or minimal. On the other hand, all four studies indicated substantial activity of 
intravesical gemcitabine, even in BCG refractory patients. To test the potential and risks of 
gemcitabine when used intravesically in humans, we designed a phase I study with 
pharmacokinetics with different dosages of gemcitabine, given 6 times weekly with a one 
hour instillation time. 
 
 
Material and Methods 
 
Approval was granted from the Medical Ethical Committee of the University Medical Centre 
Nijmegen, The Netherlands, before the study was undertaken. All patients were given written 
information and written informed consent was obtained. 
Primary study objective was to define the optimal dose of intravesical gemcitabine with 
regard to local and systemic toxicity. Secondary objectives were the safety profile, 
pharmacokinetic results and the recurrence free interval. The study was a single centre, open 
label, non-randomised phase I study. 
Patient inclusion criteria were any superficial TCC, except pT1grade3, CIS or TCC outside 
the bladder, after a complete TUR. Previous intravesical therapy was allowed, except 
gemcitabine, as long as this took place more than 6 months before study entry. Further criteria 
were performance status 0-2, age <85 years, normal blood counts and informed consent. 
Additional exclusion criteria were uncontrollable infection, concurrent malignancy and 
pregnancy or lactation. Pre study evaluation included routine examination, routine blood tests 
and urinary cytology. After standard complete TUR without random biopsies the treatment 
plan was a course of 6 weekly instillations with 1000, 1500 or 2000 mg gemcitabine 
(provided by Lilly, Houten, the Netherlands) in 50 cc 0.9% saline for one hour as an 
outpatient procedure. Dose modifications and/or extra patients treated at the same dose level 
were extensively defined in case of dose limiting toxicities. Only when no patients per dose 
level experienced dose-limiting toxicity, the next cohort of three patients could be enrolled 
and treated at the next dose level. Local and systemic toxicity was scored according to NCI-
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CTC version 2.0 criteria. Blood samples during gemcitabine therapy were taken before, and 5, 
30, 60 (=evacuation) and 120 minutes after instillations number 1, 3 and 6, in tubes containing 
tetrahydrouridine to prevent deamination of gemcitabine. Samples were used for red and 
white blood counts and pharmacokinetics. Evaluation after instillation therapy included 
cystoscopy and cytology at months 3, 6, 9 and 12. 
 
 
Pharmacokinetics 
 
Pharmacokinetic methods have been described in detail before14. In short, blood samples were 
collected in heparin tubes containing 10 µl of THU (1 mg tetrahydrouridine/ml phosphate 
buffered saline) and mixed. Thereafter, the tubes were immediately placed on ice and 
transferred to the lab for centrifugation, after which the plasma was stored at –20ºC until 
further processing in Amsterdam as one batch. The buffy coat was diluted with phosphate 
buffered saline and the white blood cells were isolated using centrifugation, washed, counted, 
frozen and stored at –80oC. Subsequently, all compounds were extracted from plasma or 
white blood cells and determined by means of HPLC analysis. The analysis of dFdC and 
dFdU was performed with ion pair-reversed phase separation and dFdCTP with anion 
exchange separation14. The analytical results of a series of samples was only acceptable when 
the regression coefficient of the calibration line was >0.99 and when the relative error of three 
quality controls was less than 15%. The limit of quantification (LOQ) for dFdC and dFdU is 
0.5 µM plasma concentration. The detection limit was 0.1 µM for both compounds. The LOQ 
for dFdCTP is 50 pmol. 
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Results 
 
Between September 2001 and March 2002, 3, 4 and 3 patients were treated with 1000, 1500, 
and 2000 mg gemcitabine, respectively. The fourth patient in the 1500 mg dose level was 
included because she insisted, based on information by a fellow patient. All tumours were 
pTa, multiple in 8 of which 3 had more than 10 tumours at study entry. Six patients had grade 
IIa tumours, 4 grade IIb. Two tumours were primary, 2 patients had their first recurrence, and 
the other 6 patients were highly recurrent (recurrences more than once yearly). Seven patients 
experienced side effects: 2 with dysuria after the first instillation, 2 after instillations 3-6 and 
4-6; in 3 patients headache, fatigue and heavy legs were experienced once. There was no 
correlation between side effects and extend of TUR. All side effects were reversible, non-
limiting and WHO 1. No macroscopic haematuria or other adverse events were seen. In 
patient #1 (aged 78 years, dose 1000 mg) WBC dropped from 6.5 before therapy to 2.8 after 
the first instillation, but was normal during instillation 3 and 6. No other haematological 
abnormalities were seen in any patient. Gemcitabine plasma levels were very low. Patient #1 
had the highest plasma level after the first instillation (0.91uM). All other levels were 
immeasurable or lower, with peak levels between 30 and 60 minutes, which decreased after 
more instillations (p=0.032) (Fig 1). Plasma levels of dFdU were measurable in all patients, 
with a maximal level of 4.19 µM in patient #5 (1500 mg) 60 minutes after the first instillation. 
In 4 patients peak levels exceeded 2 µM at the first instillation, while in the other patients 
levels remained below 1 or around 1 µM. Again, peak levels decreased significantly (p=0.014 
and 0.004) with more instillations (Fig 2). The active metabolite of gemcitabine, dFdCTP, 
was only measurable in the first patient, which also showed a decrease in white blood cells. 
The peak level at the first administration was 110 and 109 pmol/106 cells (60 and 120 min, 
respectively). At second sampling these values were 44 and 48 pmol/106 cells and at third 
sampling the concentration was not detectable. The concentration of gemcitabine and dFdU 
showed a similar pattern. 
Preliminary efficacy results of the 6 highly recurrent patients (recurrence rate >1/yearly) 
showed in all cases recurrent disease after 6 to 18 months. Patients were treated additionally 
and were all free of disease progression. The 4 low risk patients are still recurrence free after a 
follow-up period of 30 to 36 months.  
 
 91
Chapter 6 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0 5 30 60 120 0 5 30 60 120 0 5 30 60 120
Instillation 1, 3 and 6, time in minutes
uM
 
 
Figure 1.  Plasma dFdC level in patient 8 (2000 mg/50 ml), at fixed time points during and after 
instillation 1, 3 and 6.  
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Figure 2.  Plasma dFdU level in patient 8 (2000 mg/50 ml), at fixed time points during and after 
instillation 1, 3 and 6.  
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Discussion 
 
In this paper we demonstrate that gemcitabine is very well tolerated when given 
intravesically. Up to now, gemcitabine is usually given systemically and shown to be well 
tolerated. It is proven to be effective against pancreatic, ovarian and non small-cell lung 
tumours. Toxicity includes mild myelosuppression in most patients, abnormalities in hepatic 
transaminase enzymes in two-thirds of patients, skin rash in 30% and nausea, vomiting and 
flu-like symptoms in 20%. Gemcitabine monotherapy was shown to be effective in advanced 
bladder cancer with objective response rates between 11% and 28%, even in cisplatinum 
pretreated patients15-18. Combinations of gemcitabine showed objective response rates 
between 54 and 68% with mild toxicity, although 2 leukopenic deaths were reported19-23. In a 
large phase III study gemcitabine and cisplatinum (GemCis) was compared to MVAC 
(methotrexate, vinblastin, doxorubicin and cisplatinum) in locally advanced or metastatic 
TCC. GemCis had a better safety profile and a similar survival advantage, although the trial 
was not designed as an equivalence trial24. 
In all, gemcitabine seems to be one of the most effective drugs against TCC, with a 
significantly higher activity than drugs that have been used intravesically so far, like 
ThioTEPA, doxorubicin, epirubicin and mitomycin-C. Cisplatinum could have been an 
alternative, but treatment efficacy in superficial bladder cancer appeared to be disappointing, 
and more important, in almost 10% of patients anaphylactic reactions occurred due to the 
intravesical administration25,26. An EORTC trial (30782) with intravesical cisplatinum was 
closed for this reason. 
Gemcitabine has several features that make it an attractive alternative chemotherapeutic agent 
for intravesical use in patients with TCC.  The single-agent activity against TCC is 
significant. The molecular weight of gemcitabine (299,66 D) is high enough to assume there 
will be no systemic absorption in case of an intact bladder wall. Furthermore, the systemic 
toxicity profile is mild, so in case of systemic absorption the consequences would be minimal. 
The systemic absorption was indeed minimal. Plasma concentrations were much lower than 
that observed when similar doses of gemcitabine would be given systemically; peak plasma 
concentrations would be 20-30 µM14. 
The intravesical administration of gemcitabine has been tested in animal models and in two 
phase I trials. Cozzi et al. used gemcitabine during 4 weeks in a frequency of three times 
weekly in dogs10. They found systemic absorption, especially at the end of the instillation 
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period, but concluded that it was possible to deliver a clinically active dose without bladder or 
systemic toxicity. We performed a study in pigs, with 6 weekly instillations11. We did not find 
any problems with the animals well being, bladder toxicity or systemic toxicity either, neither 
did we find systemic absorption. Explanations for this dissimilarity can be the difference in 
instillation schedule: once weekly in pigs versus 3 times weekly in the dogs. 
Two phase I studies with intravesical gemcitabine have been published to date12,13.  
Dalbagni et al treated 18 BCG refractory patients that refused cystectomy, twice weekly with 
intravesical gemcitabine, 1 hour with a 100 mL solution12. They used doses of 500 (N=3), 
1000 (N=6), 1500 (N=3) and 2000 (N=6) mg. In the 1000 mg dose level one patient had a 
grade 3 skin reaction, and at the 2000 mg level one patient had a grade 3 thrombocytopenia 
and neutropenia. In all, bladder symptoms were minimal, and myelosuppression tolerable. 
Seven patients had a complete response, indicating substantial activity of Gemcitabine, even 
in BCG refractory patients. Laufer et al. performed a dose finding study with 
pharmacokinetics in 15 patients with recurrent superficial bladder cancer13. Gemcitabine was 
given once weekly for 6 consecutive weeks, with a 2 hours instillation time. The used doses 
were 500, 1000 and 1500 mg in 100 mL in 3 patients each, and 2000 mg in 100 mL (N=2) 
and 50 mL (N=4). No grade 4 toxicity or clinically relevant myelosuppression was seen. At 
12 weeks 9 of 13 evaluable patients were recurrence-free. No gemcitabine was found in 
plasma, except for low plasma concentrations of gemcitabine (<1 µg/mL) in the 4 patients 
receiving 2000 mg in 50 mL. dFdU was undetectable in doses less than 1500 mg. At doses 
>1500 mg, dFdU was found in some patients, with peak concentrations at 90 to 120 minutes. 
They also concluded that intravesical gemcitabine, even at 2000 mg, was well tolerated with 
minimal systemic absorption, and promising efficacy. 
Our results also indicate very limited local (bladder) and general toxicity, and minimal 
systemic absorption. In our study toxicity was never more than grade 1. Since we used a once 
weekly instillation schedule with a one hour instillation time, the normal routine in instillation 
therapy, the side effects are obviously less than in the two other studies, where they used 
weekly instillations with a 2 hour instillation time or a twice weekly schedule with a 1 hour 
instillation time. Moreover, we used an instillation volume of 50 mL, whereas the other two 
studies predominantly used 100 mL, which can cause more local problems for the patient. As 
in the study of Laufer et al., gemcitabine levels in our study were low or immeasurable, with a 
highest value of 0.91 µM. Plasma dFdU levels also showed a trend similar to that study. 
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Preliminary efficacy was encouraging, showing that gemcitabine has potential in several areas 
of patients with superficial bladder cancer. 
 
 
Conclusion 
 
 Intravesical gemcitabine in the dose and schedule used has minimal ( < grade 1) and 
reversible local and systemic side effects. Pharmacokinetic evaluation indicates that its 
intravesical use is safe. Early efficacy results of this study and two other studies underline the 
potential of intravesical gemcitabine in several patient groups with superficial bladder cancer. 
Further studies will show the optimal dose and schedule, as well as the best indication for 
intravesical gemcitabine. 
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Abstract 
 
To study the ablative activity of intravesical EOquinTM (apaziquone, EO9) on a papillary 
marker tumour and to determine the incidence of side effects.  
Forty-six patients with multiple pTa or pT1 bladder tumours had all visible lesions resected 
except for one marker tumour. Patients were then treated with 6 instillations of EO9 at weekly 
intervals. Response was determined 2 to 4 weeks after the last instillation. 
One patient withdrew informed consent and refused the last treatment due to side effects.  
Histologically proven complete response was seen in 30 patients. Progression to invasive 
stage was not observed. Local side effects in this study were comparable with those due to 
other chemotherapeutic instillations such as MMC and epirubicin, but less severe and less 
frequent compared to BCG instillations.  
The histological complete response rate after 6 consecutive instillations of EO9 in patients 
with superficial bladder cancer was 65% (95% confidence interval 50-79%). Local side 
effects were comparable with side effects due to other chemotherapeutic instillations. 
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Introduction 
 
Bladder cancer is the seventh most common cancer worldwide, accounting for 3.2% of all 
cancers. The highest incidence rates of bladder cancer in both sexes are observed in Europe, 
North America and Australia1. Bladder cancer incidence is rising moderately in most 
developed countries. In the United Stated the estimated number of new bladder cancer cases 
in 2005 is 63,210 (47,010 in men and 16,200 in women)2. However, the mortality rate is 
relatively low because more than 90% of all malignant bladder tumours are transitional cell 
carcinomas, two thirds of which are superficial and one third muscle invasive.  
The initial management of superficial bladder cancer consists of transurethral resection. 
Despite the most accurate resection techniques, about 30 to 85% of patients develop 
recurrences depending on the stage and grade of the bladder tumour. Tumour recurrence after 
transurethral resection may occur by various mechanisms. Residual cancer cells may grow 
locally or be disseminated over the urothelium due to damage caused by transurethral 
resection. Furthermore, pre-existing microscopic lesions may grow into visible tumours. 
These recurrences can be prevented with chemotherapeutic or immunotherapeutic agents. 
Immunotherapy (BCG) lowers the recurrence rate significantly and has a limited effect on the 
progression rate3. The side effects of BCG, however, are more frequent and more severe than 
those associated with chemotherapy agents. There is a need for more effective and safer 
treatment. 
EOquinTM (apaziquone USAN, EO9) is an indoloquinone derivative of the clinically used 
anti-cancer drug Mitomycin-C(MMC). As in the case of MMC, EO9 belongs to the bio 
reductive drugs. These drugs are inactive prodrugs which require activation by cellular 
reductase enzymes in order to become cytotoxic4. 
In preclinical research the concentration of EO9 to reach 50 percent cell kill (LD50) at 37 ºC 
was 6 to 78 times lower than that of MMC, depending on the type of bladder cancer cell line 
used5. In the present study, efficacy (ablative activity) and side effects of EO9 instillations are 
tested on a papillary marker tumour in patients with intermediate or high risk superficial 
bladder cancer.  
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Material and Methods 
 
Inclusion criteria 
 
All patients had primary or recurrent, multiple (but no more than ten) histologically confirmed 
Ta or T1, GI or GII transitional cell carcinoma of the bladder. All visible tumours had to be 
completely removed by transurethral resection, except for a marker lesion measuring between 
0.5 and 1.0 cm. The marker tumour size was estimated with the size of the resection loop (0.6 
cm) as a reference. Resected tumours had to contain muscle in the specimen to confirm 
superficial disease. Random biopsies of normal-appearing mucosa were taken. 
Patients with muscle invasive disease, carcinoma in situ or grade 3 tumours were excluded. 
Patients with prior systemic or local chemotherapy or immunotherapy within the last three 
months were ineligible.  
 
 
Instillation Regimen 
 
Instillations started within 15 days after complete transurethral resection of all tumours except 
the marker tumour. Patients were scheduled to receive 4 mg of EO9 in a 40 mL instillation 
once a week for six consecutive weeks. EOquin™ and solvent for reconstitution were 
provided by Spectrum Pharmaceuticals. Prior to instillation, 4 mg of lyophilized powder was 
reconstituted with 20 ml of solvent, and then further diluted to 40 ml with water for injection. 
The drug was then injected very slowly over a few minutes (3-5 minutes).   
Once the drug was delivered the syringe was disconnected and the catheter was removed.   
EOquin was retained in the bladder for one hour and patients were discouraged from voiding 
during this time.  Patients were monitored during the retention time for the development of 
local toxicities.  The retention time was recorded.  One hour after the instillation, patients 
were asked to void in a normal toilet.  The urinary output was not measured.   
On each occasion, urine analysis and culture were performed and possible side effects were 
recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) 
version 3. Whole blood count, kidney and liver function tests were obtained every two weeks. 
If side effects occurred the dose could be reduced or the instillation delayed. 
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After completion of the six-week treatment course the tumour response was evaluated by 
video-assisted resection two to four weeks following the last instillation. Residual tumour, if 
present at this evaluation, had to be resected. In case of a complete response, the former 
tumour area (marker lesion site) had to be re-biopsied. If no complete response was achieved 
further therapy was left to the judgment of the investigator. 
 
 
Definition of response 
 
Complete response (CR) was defined as complete disappearance of the marker lesion, 
confirmed by negative biopsy at the site of the marker lesion and the absence of new tumours 
elsewhere. Progressive disease (PD) was the occurrence of a tumour with a stage greater than 
T1 (either in the marker lesion or at another site). No response (NR) is defined as the 
persistence of the marker lesion with a stage ≤ T1 or the appearance of new lesions with stage 
≤ T1. Partial response was not taken into account because of the limitations in measurements. 
 
 
Statistical consideration 
 
The main end point in this trial was the CR rate after 6 consecutive EO9 instillations. The 
study was performed in two parts. In the first part 13 patients were treated. If no response was 
seen in the first 13 patients, the probability of a response rate of at least 30% would have been 
less than 1% and the trial terminated. The second part started when at least one CR was seen 
in the first 13 patients. It was expected then that a CR rate of approximately 50% would be 
achieved. Under this assumption 44 evaluable patients would be needed to confirm the 
possibility of a 50% response rate with a power of 80% and alpha error of 5% (power = 1- 
beta error)  and to reject with the same power a response rate of less than 30%. 
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Results 
 
Between January 2004 and January 2005, forty-six patients were entered into the study by 6 
different centres in the Netherlands and 1 centre in the United Kingdom. Of these patients, 42 
(91%) were males and 4 (9%) females. The age of the patients varied from 37 to 93, with a 
median of 67.5 years. Body weight ranged from 61 to 140 kg (median 85 kg). Nine patients 
had multiple primary disease and 37 had multiple recurrent disease. The number of tumours at 
entry varied between 2 and 10, with a median of 3 tumours. The tumour characteristics of 
recruited patients are shown in table 1. Three patients, formally ineligible, were admitted after 
review and approval by the principal investigator. 
 
 
Primary disease Recurrent disease Total Tumour stage (WHO) 
N % N % N % 
TaG1 
TaG2 
T1G1  
T1G2 
T1G3 
0 
7 
0 
1 
1 
0 
78 
0 
11 
11 
10 
21 
1 
5 
0 
27 
57 
3 
14 
0 
10 
28 
1 
6 
1 
22 
61 
2 
13 
2 
Total 9 100 37 100 46 100 
 
Table 1.  Tumour characteristics of recruited patients (N=46) 
 
 
The number of previous transurethral resections for a bladder tumour and the number of 
previous courses of intravesical prophylaxis are listed in table 2 and 3, respectively. Forty-five 
patients received the 6 consecutive 40 mL instillations with 4 mg EO9 each. One patient 
withdrew informed consent and refused the last treatment (instillation 6) due to haematuria 
and dysuria. This patient had a cystoscopical complete response.  
Vital signs, including pulse, blood pressure and temperature, did not change significantly 
during treatment.   
 
 
 105
Chapter 7 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
N previous TUR N patients  
0 
1 
2 
3 
4 
5 
6 
≥7 
9 
9 
7 
5 
4 
2 
4 
6 
 
Table 2.  Previous transurethral bladder tumour resections (N=46). 
 
Previous intravesical prophylaxis N patients 
BCG 
Epirubicin 
MMC 
BCG + Epirubicin 
BCG + MMC  
Epirubicin + MMC 
BCG + Epirubicin + MMC 
BCG + MMC + Gemcitabine 
Epirubincin + MMC + Gemcitabine 
BCG + Epirubicin + MMC + Gemcitabine 
None 
1 
1 
13 
2 
6 
1 
2 
1 
1 
1 
17 
 
Table 3.  Previous intravesical anti-cancer therapy (N=46). 
 
Fifteen patients needed postponement of EO9 instillation for 1 week. Reasons for treatment 
delay were urinary tract infection (in 5 patients, 2 of whom had urinary tract infection at study 
entry), pyelonephritis (1), bladder spasms (2), urgency (3), dysuria (1) and haematuria (3). 
All side effects, possibly, probably or definitely related to the treatment, are summarized in 
table 4. Serious adverse events are summarized in table 5. In one patient the blood 
haemoglobin levels decreased slightly (CTCAE grade 1) after the third and fifth instillation, 
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due to gross haematuria. One patient exhibited an increase in lymphocytes from CTCAE 
grade 0 to 1. There were no other significant changes in haematology or blood chemistry 
during the EO9 instillations.  
The overall response in 45 patients is shown in table 6. Histologically confirmed CR was 
found in 30 patients (65%, 95% confidence limits 52-80%). The patient who withdrew 
informed consent had a tumour-free bladder after five consecutive instillations but refused 
biopsy. No appearance of new lesions in other sites was observed in patients with a CR of the 
marker lesion. NR (stable marker lesion, no new tumours) was seen in 15 patients. PD was 
not observed.  
 
 
 
CTCAE Grade Symptoms 
1 2 3 4 5 
Total number of 
patients 
Pain  1 1   General 
Fatigue 1     
2 
1 
Pyrexia 2     
 Polymyalgia 1     
2 
1 
 Headache 2     2 
Urological Pyelonephritis  1    1 
 Urinary tract infection  2 1    3 
Chemical cystitis   1   1 
Bladder pain 1 2    3 
Bladder spasm 1     1 
Dysuria 10 3    13 
Haematuria 7 7 1   15 
Haemorrhage urinary tract 2 5    7 
Micturation urgency 4 2 1   7 
Pollakisuria 5 2 2   9 
Incontinence 1 1    2 
Genital pain  1    1 
 Genital pruritis 3     3 
Table 4.   Side effects reported during treatment according to the CTCAE, worst grade per patient, 
possibly, probably or definitely related. 
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SAE CTCAE  Outcome Relation Action 
Bladder perforation 
Chemical cystitis 
Haematuria 
Urinary frequency 
Grade 3 
Grade 3 
Grade 2 
Grade 3 
Recovered 
Recovered 
Recovered 
Recovered 
Unrelated 
Probable 
Probable 
Probable 
None 
None 
Discontinued 
None 
 
Table 5.  Serious adverse events (SAE). 
 
Response to therapy N patients % (95% CI) 
Complete response 
No response (new lesion) 
No response (stable marker lesion) 
Progressive disease 
30 
0 
15 
0 
67 (0.5105 - 0.8000) 
 
33 (0.2000 - 0.4895) 
Total patients 45 100 
 
Table 6.  Marker lesion response in 45 patients two to four weeks after end of treatment. 
 
 
Discussion 
 
For more than four decades intravesical chemotherapy has been applied as adjuvant therapy 
for patients with superficial bladder cancer. Many questions about the efficacy of intravesical 
chemotherapy remain unanswered. This is due to the fact that many trials are performed in 
patients with no measurable tumour. It is logical to test new drugs on a measurable cancer 
lesion6. It offers individuals the prospect of avoiding treatment with an ineffective agent. The 
EORTC-GU Group and the Medical Research Council have demonstrated that this method is 
safe. In five phase II studies the rate of progression to muscle invasive disease was less than 
1%7.  
In order to minimize the chance of progression in the present study, the former tumour area 
had to be biopsied in case of a complete response. Nevertheless, Oosterlinck et al. studied the 
frequency of positive biopsies after visual disappearance of the marker lesion and concluded 
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that the number of positive biopsies after chemo resection is only 3% and thus the 
transurethral resection can be omitted when there is a macroscopic complete response8.  
In the present study response was classified as complete response or no response. In the 
literature it is common practice to consider a 50 percent reduction in size of measurable 
lesions as a partial response. Due to the fact that cystoscopic measurement is subjective, this 
partial response category was not considered in our study. The histologically proven complete 
response rate after 6 consecutive weekly instillations of EO9 was 65%, comparable to the 
results of another marker lesion study using 8 consecutive epirubicin instillations6. The 
response rate in other marker lesion studies using other cytostatics was inferior with a similar 
sample size and not in all cases histologically proven (Table 7).  
In the last decade EO9 has undergone clinical evaluation against a range of tumour types but 
failed to demonstrate activity when administered intravenously. Reasons for the absence of 
tumour response could be the rapid removal from the blood stream and poor penetration 
through avascular tissue9.  
 
 
Reference Agent Courses (N) Patients (N) CR marker  
Brausi et al. 1998 
Bono et al. 1996 
Heney et al. 1988 
Mack et al. 2001 
Bono et al. 1996 
Calais da Silva et al. 1988 
Newling et al. 2001 
Heney et al. 1988 
MMC  
MMC  
MMC  
BCG (quarter dose) 
Epirubicin  
Epirubicin 
Valrubicin  
ThioTEPA  
8 
8 
8 
6 
8 
8 
6 
8 
12 
96 
76 
44 
36 
45 
39 
73 
41.6% 
57.3%1 
39.5% 
61.4%1 
66.7%1 
46.7%1 
46.2% 
26.0% 
1 The complete response was not in all cases histologically proven 
 
Table 7.   Results of several marker lesion studies with intravesical chemotherapeutic or 
immunotherapeutic agents  
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While these properties are a problem in terms of treating systemic disease, they can be ideal 
for treating cancers which arise in an anatomically accessible site such as the bladder. Drug 
delivery is not a problem, as drugs are instilled in the bladder via a catheter. Any drug 
reaching the blood stream would be rapidly removed10,11 and therefore the risk of side effects 
to other tissues is low.  
Furthermore EO9 is a bio-reductive drug, so it requires activation by cellular reductase 
enzymes. In the case of EO9 the enzyme DT-diaphorase plays a central role in activating the 
drug. Several tumours have high levels of DT-diaphorase activity compared with normal 
tissue, suggesting that selective toxicity against tumour cells may be achieved. In more than 
40% of patients suffering from bladder cancer, the level of DT-diaphorase in bladder tumour 
tissue is higher compared to normal tissue12.  
Another reason to use EO9 in bladder cancer is the fact that systemic toxicity is theoretically 
rare. Systemic toxicity depends on penetration of the drug through the bladder wall into the 
blood stream. The molecular weight of 288 limits penetration of EO9 through the bladder 
wall. Furthermore, EO9 is rapidly cleared from the systemic circulation, suggesting that 
systemic toxicity will probably be low or non-existent considering the fact that substantially 
lower total doses are used intravesically, as compared to systemic therapy studies10,11. Also, 
EO9 and known metabolites were consistently undetectable by HPLC in the 12 patients of a 
phase I study, 30 and 60 min after the start of intravesical instillation with doses ranging from 
4 mg to 16 mg in 40 mL13. Finally, EO9 can be potentiated under acidic extracellular pH (for 
example pH 6.0) conditions, but may lose activity in the blood stream due to an increase in 
extracellular pH to 7.35-7.45. These observations make systemic toxicity unlikely. 
In the present study one patient exhibited a fall in haemoglobin level from CTCAE grade 0 to 
1 due to haematuria and one patient exhibited an increase in lymphocytes level from CTCAE 
grade 0 to 1. No other systemic side effects were seen. 
Local side effects due to EO9 instillations are more frequent. Allergic reactions seen as 
genital pruritus were observed in 3 (6.5%) patients. In the EORTC study 30864 assessing the 
tolerability and ablative capacity of MMC, 99 of 108 eligible patients completed the full cycle 
of eight treatments and the commonest side effect was allergic reaction, observed in 16 out of 
108 patients (14.8%)9. Five patients (4.6%) had to stop treatment. In the EORTC study 30869 
assessing the tolerability and ablative capacity of epirubicin, 39 of 40 eligible patients 
completed the full cycle of eight treatments and here allergic reaction was found in 3 (7.5%) 
patients9. 
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In the present study chemical cystitis that required delay in treatment was observed in 1 
(2.2%) patient. In the EORTC study 30864 (MMC) chemical cystitis severe enough to stop 
treatment was seen in 2 (1.9%) patients. In the present study bacterial cystitis was observed in 
3 (6.5%) patients. In the EORTC study 30864 (MMC) bacterial cystitis was seen in 9 (8.3%) 
patients, in the EORTC study 30869 (epirubicin) it occurred in 6 (15%) patients and in the 
study of Melekos et al. it was seen in 5 (11.4%) patients treated with intravesical BCG 14.  
In the prospective comparative study of Melekos et al. intravesical epirubicin (N=67) was 
compared with intravesical BCG (N=62)12. Fever with or without chills was seen in 27.4% of 
patients treated with BCG and in 3% of patients treated with epirubicin. In the present study 
fever was observed in 2 (4.4%) patients.  
Haematuria was the most frequent side effect in the present study. It was observed in 15 
(32.6%) patients. Furthermore, nearly all patients with haematuria suffered from dysuria 
(N=13; 28.3%). One (2.2%) patient had to stop treatments due to dysuria and haematuria. In 
the study of Melekos et al. macroscopic haematuria was observed in 22.6% (BCG) versus 
15% (epirubicin). In the marker lesion study of Mack et al., in which 44 patients were treated 
with 6 consecutive ¼ dose BCG instillations, haematuria was seen in 17 (38.6%) patients, 
dysuria in 29 (65.9%) and frequency in 12 (27.3%) patients15. 
In conclusion, local side effects in this study were comparable to those due to other 
chemotherapeutic instillations such as MMC and epirubicin, but less severe and less frequent 
compared to BCG instillations.  
Currently an adjuvant phase II study on EO9 concerning patients with high grade superficial 
bladder cancer is recruiting patients. A phase III comparative study with EO9 versus BCG in 
patients with high risk superficial bladder cancer is planned.  
 
 
Conclusion 
 
The results of this marker lesion trial using EO9 in patients with a histologically proven 
complete response rate of 65% are promising and warrant further study in patients with 
superficial bladder cancer.  
Side effects are comparable to those of other chemotherapeutic agents currently used for 
superficial bladder cancer, but less frequent and less severe compared to BCG treatment.  
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Abstract 
 
Superficial bladder cancer can be treated by transurethral resection (TUR) and adjuvant 
intravesical therapy. Intravesical bacillus Calmette-Guérin (BCG) has been proven to be more 
efficacious with respect to recurrence prevention than intravesical chemotherapy, although at 
the cost of more severe side effects. So, there is a need for a new treatment modality with 
higher efficacy and less toxicity. The subject of this study is the efficacy of local microwave 
hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional 
cell carcinoma (TCC) of the bladder.  
Ninety eligible patients received adjuvant treatment with a combination of mitomycin-C 
(MMC) and local microwave hyperthermia. All patients had multiple or recurrent Ta or T1 
TCC of the bladder and were classified as intermediate or high risk according to EAU criteria. 
In total, 41 patients were BCG failures. The treatment regimen included 6 to 8 weekly 
sessions followed by 4 to 6 monthly sessions. Follow-up consisted of video-cystoscopy and 
urine cytology every 3 months. All patients were observed for 2 years. 
Kaplan-Meier analyses of the total group (N=90) indicated that 1 year after treatment only 
14.3% (SE 4.5%) of all patients experienced a recurrence. After 2 years of follow-up the risk 
of recurrence was 24.6% (SE 5.9%). No progression in stage and grade was observed. 
Microwave induced hyperthermia combined with MMC has promising value in intermediate 
or high risk superficial bladder cancer patients compared to literature data of BCG and/or 
intravesical chemotherapy, particularly where other treatments, i.e. BCG, have failed. 
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Introduction 
 
Superficial transitional cell carcinoma (TCC) of the bladder has a high incidence and an even 
higher prevalence because of its high recurrence rate (30-85%) after primary transurethral 
resection (TUR)1. Intravesical instillations are used to lower the recurrence rate and the risk of 
progression to muscle invasive disease. Intravesical instillations can either be 
chemotherapeutic or immunotherapeutic.  
In a meta-analysis of randomized trials by the EORTC and MRC, Pawinski et al. showed that 
after 5 years of follow-up the group treated with intravesical chemotherapy had a 6% lower 
recurrence rate as compared to the untreated group2. Several other studies showed that the net 
benefit after one year of follow-up is 12% for patients treated with mitomycin-C (MMC) 
compared to patients without adjuvant treatment3;4. However, intravesical chemotherapy had 
no impact on progression to muscle invasive disease. Intravesical bacillus Calmette-Guérin 
(BCG) has been shown to reduce the recurrence rate after TUR to a larger extent than 
intravesical chemotherapy5. Recent data have shown that BCG can even delay tumour 
progression6, although at the cost of more frequent and more severe side effects. In all, there 
is a need for a new treatment modality with higher efficacy combined with less toxicity. In 
several studies thermo-chemotherapy seems to be effective and side effects are tolerable7-10. 
The combination of thermal energy and chemotherapy offers several advantages over 
chemotherapy alone: drug uptake by the malignant cells and intracellular distribution are 
improved by increased cellular permeability; reaction of chemotherapy with DNA is increased 
and DNA repair is inhibited11. In theory, the bladder tissue is heated to obtain an accelerated 
series of reactions of the MMC. Based on Moore's model of MMC activation, 5 reactions 
contribute to link MMC to the DNA of the cells. Heating will accelerate this reaction 
considerably. Applying thermal energy to the bladder provides another theoretical advantage, 
the pathological blood vessels nourishing the tumour lack the ability to vasodilate in response 
to heat the way normal blood vessels do. Thus, the lesions attain higher temperature in 
comparison with normal tissue. These advantages were translated into a clinical benefit as 
shown by a randomized study comparing the ablating power of combined thermo-
chemotherapy to intravesical chemotherapy alone9. Furthermore, several measurements show 
that MMC will not be modified by the temperature rise used during thermo-chemotherapy.  
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In this study the effects of microwave induced local hyperthermia and intravesical 
chemotherapy with mitomycin-C (MMC) are evaluated in patients with intermediate and high 
risk TCC, according to EAU criteria12.  
 
 
Materials and methods 
 
Patient selection 
 
Patients with histologically confirmed Ta or T1 multiple or recurrent superficial transitional 
cell carcinoma of the bladder were eligible for inclusion. To ensure an optimal pre-treatment 
situation at entry of the study, complete resection of all papillary tumours was required.  
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Figure 1.  SB-TS 101 system during treatment application. The applicator heats the bladder wall. 
Temperature is controlled by 5 thermocouples. The catheter is cooled and the applicator is  
flushed with MMC.  
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To make sure that the resection was radical, the pathology specimens should contain detrusor 
muscle without tumour invasion. The average delay between last TUR of the tumour and 
study entry was 55 days. During this delay patients were not treated with chemotherapeutics 
or immunotherapeutics. Upon entrance a video-cystoscopy was performed and urine cytology 
was obtained. When there were any doubts, biopsies were taken. The video cystoscopy 
enables reviewing the pre-treatment situation at any time in the future. 
Patients had to have a WHO Performance Status 0 to 2 and a life expectancy of more than 24 
months. Furthermore, only patients treated with 2 times 20 mg MMC were eligible for this 
analysis. 
Criteria for ineligibility were a bladder capacity<150mL, concomitant malignancy, 
extravesical TCC and the presence of a diverticle of the bladder. Patients without follow-up 
cystoscopy or with less than six treatments were excluded from analysis.  
 
Treatment: 
 
The system SB-TS 101 (Figure 1) used to deliver local microwave induced hyperthermia and 
intravesical chemotherapy simultaneously has been described by Colombo et al9.  
This system consists of a 915 Mhz. intravesical microwave applicator that delivers 
hyperthermia of the bladder walls via direct irradiation. The applicator is part of the specially 
designed 20F transurethral catheter (Figure 2). The catheter also contains 5 thermocouples. 
Two thermocouples measure the temperature in the prostatic urethral tract; the other three are 
spread out and pushed tangentially against the posterior and lateral walls of the bladder. To 
avoid urethral overheating and disintegration of MMC, the solution is continuously pumped 
out of the bladder and re-instilled after being cooled. 
The treatment regimen included 6 to 8 weekly sessions followed by 4 to 6 monthly sessions, 
each lasting 60 minutes. All sessions were conducted on an outpatient basis. Each treatment 
session began by inserting the transurethral catheter into the bladder. The 3 bladder 
thermocouples were spread out to contact the bladder walls. After the bladder was emptied, 
20 mg MMC (Kyowa Hakko Kogyo Co., Tokyo, Japan) in 50 mL distilled water was instilled 
(Figure 3).  
In order to stabilize the MMC concentration in the bladder throughout the entire session, the 
bladder was emptied after 30 minutes and the with urine diluted solution was replaced by a 
new solution containing 20 mg MMC. Hyperthermia was delivered within a temperature 
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range of 41°C to 44°C. In case of significant bacterial cystitis or haematuria, treatment delay 
was recommended. Clinical complications and other intercurrent events were reported in the 
patients’ personal file.  
 
 
Follow-up 
 
Video-cystoscopy and urine cytology were repeated every 3 months for a follow-up period of 
24 months. Biopsies from suspicious lesions were performed. The primary end point for 
patients was either a pathology proven tumour recurrence, or a clear cystoscopical recurrence 
indicated by the investigator.  
Data were collected during the treatments and follow-up. Kaplan-Meier plots were drawn to 
assess the risk of recurrence. Statistical significance of differences in risk of recurrence 
between subgroups was evaluated with the log rank test. For statistical analysis, the software 
program SPSS for Windows version 11.0 was used.  
 
 
Results 
 
From March 1994 until April 2003, 115 patients of 9 European hospitals were entered, 90 of 
whom were eligible. Reasons for ineligibility are listed in table 1. In total, 78 men and 12 
women 35 to 92 years old (mean age 64.8) underwent radical transurethral resection of a 
superficial transitional cell carcinoma (TCC) of the bladder. A history of recurrent disease 
was evident in 76 patients despite previous chemoprophylaxis in 15 patients, 
immunoprophylaxis in 22 patients and both chemo- and immunoprophylaxis in 19 patients. 
 
 
Reason for ineligibility No. (%)  
 
Small bladder volume 
MMC concentrations other than 2 times 20 mg  
Concomitant malignancy 
Extravesical TCC 
No follow-up cystoscopy or less than 6 treatments 
 
2 (8%) 
4 (16%) 
1 (4%) 
4 (16%) 
14 (56%) 
Table 1.  Reasons for ineligibility (N=25) 
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Figure 2.  MMC instillation and specially designed 20F transurethral catheter. 
 
Figure 3.   Start of treatment session after MMC is instilled intravesically. 
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In total, 34 patients have had no previous chemo- or immunoprophylaxis. Sixteen of these 34 
patients had primary disease. Eighteen patients had recurrent disease and were not treated 
with chemotherapy or immunotherapy. All these patients had a previous low or intermediate 
risk TCC. Tumour characteristics and previous prophylaxis treatments are summarized in 
table 2. 
In the early years of the study period there was less consensus in adjuvant treatment policy of 
superficial bladder cancer patients. Therefore, thermo-chemotherapy was considered an 
alternative to chemotherapy or immunotherapy in these untreated patients. With current 
guidelines, however, these patients are treated with (one immediate) instillation of 
chemotherapy.  
 
Previous prophylaxis 
 
EAU risk 
Intermediate  
EAU risk 
High 
Multifocal Recurrent High 
Recurrent  
 
BCG (N=22) 
MMC (N=7) 
EPI (N=5) 
BCG + EPI (N=6) 
BCG + MMC (N=10) 
EPI + MMC (N=3) 
BCG + EPI + MMC (N=3) 
None (N=34) 
 
5 
3 
2 
4 
 
1 
 
22 
 
17 
4 
3 
2 
10 
2 
3 
12 
 
8 
5 
2 
4 
2 
 
1 
17 
 
6 
5 
3 
4 
1 
1 
 
12 
 
16 
2 
2 
2 
9 
2 
3 
6 
 
Total 
 
37 
 
53 
 
39 
 
32 
 
42 
 
Table 2.   Tumour characteristics (N=90) and previous endo-vesical prophylaxis. Recurrent disease is <3 
episodes in 2 years; High Recurrent is ≥3 episodes in 2 years. 
 
 
Treatment results 
 
The mean number of treatments was 10 ± 2 in 90 patients. Pathology proven tumour 
recurrence was seen in 14 patients of whom 5 had multiple lesions. Progression in stage and 
grade was not seen during the follow-up period (mean 18 months; range 4 to 24 months). 
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Kaplan-Meier analyses of the total group (N=90) indicated that the risk of recurrence after 1 
year follow-up was 14.3% (SE 4.5%), while the risk of recurrence was 24.6% (SE 5.9%) after 
2 years of follow-up (Figure 4).  
Patients with intermediate risk TCC had a statistically significant longer time to recurrence 
and a lower risk of recurrence compared to patients with high risk TCC (Figure 5). 
Kaplan-Meier analysis for the patients with prior BCG treatment indicated that the risk of 
recurrence after one year of follow-up was 23.1% (SE 7.7%), while the risk of recurrence was 
41.2% (SE 9.9%) after 2 years of follow-up (Figure 6). 
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Figure 4.  Kaplan-Meier (one minus survival) curve for time to first recurrence among all eligible patients 
(N=90) after start treatment. The percentage of patients who were recurrence free at 1 year and 
2 years were 85.7% and 75.4%, respectively. 
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Figure 5.  Kaplan-Meier (one minus survival) curves for time to first recurrence among patients with high 
risk TCC (solid line) and intermediate risk TCC (dotted line). At 24 months 64% and 92% of 
patients with high risk TCC and intermediate risk TCC, respectively, were disease free. Log 
rank test: p=0.03. 
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Figure 6.  Kaplan-Meier (one minus survival) curve for time to first recurrence among patients who 
received prior treatment with BCG. The percentage of patients who were recurrence free at 1 
year and 2 years were 76.9% and 58.8%, respectively.   
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Side effects 
 
In total, 65 patients experienced one or more side effects (table 3). In all occurrences side 
effects were localized and transient during treatment and resolved without any residual 
effects. The posterior wall thermal reaction, typical for thermo-chemotherapy, appeared as a 
discoloured patch surrounded by hyperaemia. In general, these lesions were asymptomatic 
and healed spontaneously. However, there was one case of severe and prolonged thermal 
reaction (though a-symptomatic), consisting of a lesion greater than 2 cm in diameter of 
which healing took more than 3 months.  
Tissue reaction was seen in 24% of all patients and was characterized by redness and/or 
oedema or any other effect seen on the bladder wall, except the thermal reaction on the 
posterior wall. 
There was no significant difference in side effects and clinical complications between the 9 
participating hospitals. 
 
 
Side effects  
 
No. (%) 
 
Dysuria 
Haematuria 
Pain 
Posterior wall thermal reaction (Figure 7) 
Skin allergy 
Urethral stenosis 
Tissue reaction 
No side effects 
 
22 (24.4%) 
8 (8.9%) 
33 (36.7%) 
23 (25.6%) 
8 (8.9%) 
4 (4.4%) 
22 (24.4%) 
25 (27.8%) 
Table 3.  Side effects (N=90) 
 
 
Discussion 
 
Adjuvant intravesical immunotherapy with Bacillus Calmette Guérin (BCG) is known to 
reduce the recurrence and progression rate6;13. Therefore, BCG treatment has become the 
standard adjuvant treatment for patients with high risk TCC5. However, since intravesical 
chemotherapy has fewer and less severe side effects, this treatment remains an interesting 
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approach. It is known from the literature that malignant cells are more sensitive to heat than 
normal cells. Hyperthermia causes inhibition of DNA, RNA and protein synthesis. These 
changes may be lethal for the cell if repair mechanisms are not effective14. Local 
hyperthermia demonstrated a synergistic cell killing effect when used in combination with 
chemotherapy for the treatment of many solid tumours, including transitional cell carcinoma 
of the bladder15;16.  
In the present study, the results of 90 eligible patients who received adjuvant treatment with 
combined thermo-chemotherapy were analyzed. The primary end point in the protocol was 
recurrent disease. The secondary end point was determined at 24 months of follow-up. The 
follow-up in the present study was relatively short; mean follow-up was 18 months, due to 
several recently included patients. However, in these high risk patients most of the 
recurrences can be expected in the first 2 years after TUR of the tumour17;18. 
 
 
 
 
Figure 7.  Posterior wall thermal reaction 
 
Patients tolerated the combined thermo-chemotherapy relatively well. Most side effects were 
localized, transient and did not influence the completion of the treatment. During the 
procedure patients generally had mild urgency but rarely mentioned urethral burning. In 
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several cases prophylactic anticholinergic drugs successfully relieved these symptoms. The 
thermal reaction on the posterior wall, found in several patients, is self limiting and 
asymptomatic. The location of this thermal reaction corresponds to the location of the tip of 
the intravesical microwave applicator that delivers hyperthermia. Only in one patient the 
healing time was extended. Systemic side effects were absent as expected from the low 
absorption rate of MMC. With a molecular weight of 334, MMC is hardly absorbed so 
myelosuppression in standard treatment regimens is rare (0.7%)9. The frequency of the well 
known allergic skin reactions on intravesical MMC also did not increase19. Recently, Paroni et 
al. found that local hyperthermia enhances the systemic absorption of MMC during combined 
thermo-chemotherapy. However, with the doses used, plasma MMC concentrations were 
always more than six times lower than those shown to cause myelosuppression (400 
ng/mL)20.  
In a prospective study among 1700 patients with primary superficial TCC, Kiemeney et al. 
showed that the risk of recurrent disease in the first year of follow-up was 33% (95% CI: 31-
35%)17. In the second year of follow-up, this risk was 47% among patients who had already 
had recurrent disease, compared to 18% of the patients without recurrence in the first year of 
follow-up. The results of the present study, where 14.3% of all patients treated with combined 
thermo-chemotherapy had recurrent disease after a follow-up of 1 year and 24.6% after a 
follow-up of 2 years, compares favourably to these results. Moreover, the prospective study of 
Kiemeney et al. also included low risk patients while the present study excluded these 
patients. On the other hand the series from Kiemeney et al. was population-based and did not 
exclude patients without radical TUR. Another difference is that all patients in the Kiemeney 
study were primary and therefore not treated with chemotherapy previously, whereas in the 
present study 34 out of 90 patients were not treated with chemotherapy before.  
Shelley et al. analysed the data of solely patients with intermediate to high risk recurrent 
disease and found a recurrence rate of 56% after one year of follow-up21. The results of the 
present study seem to be better, even compared to studies under optimal conditions. 
Furthermore, no progression or disease related mortality was seen. For example, in a 
randomized phase III study, with 63% of all patients being chemo/immuno therapy naïve, Au 
et al. found 52% and 66% recurrence in 111 patients after one and two years of follow-up, 
respectively. These patients were treated weekly for 6 weeks with 20 mg MMC without 
pharmacological manipulations18. In the same phase III study 119 patients in an optimized 
treatment arm received 40 mg MMC weekly for 6 weeks, were instructed to refrain from 
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drinking for 8 hours and were given three times 1.3 g of sodium bicarbonate before treatment. 
After one year and two years of follow-up, respectively 39% and 48% of all patients had a 
recurrence. Also in this study, patients who failed BCG treatment were included; however, the 
percentage of BCG failures was lower, namely 30% versus 46% in the present study. 
Nevertheless the present study indicates that the time to recurrence is longer in patients 
treated with 20 mg MMC combined with local bladder hyperthermia than in patients treated 
with an optimized chemotherapy treatment. Nonetheless, patients with thermo-chemotherapy 
were treated with a mean number of 10 treatments, while the patients in the study of Au et al. 
received only 6 treatments. Furthermore, the solution containing 20 mg MMC was replaced 
after 30 minutes in an attempt to stabilize the MMC concentration in the bladder, while no 
MMC replacement took place in the study of Au et al.  
Hurle et al. evaluated the long term results of patients solely with high recurrent disease, 
treated after complete TUR with 40 mg MMC in a maintenance regimen. After one year and 
two years of follow-up, 25% and 43% of all patients respectively, had a recurrence22. In this 
study the progression rate was 5.8% (14/242), with a mean time to progression of 34 months. 
In the present study no disease progression was seen, but the number of patients and the 
follow-up time is too small for definite conclusions. Furthermore, in the present study not 
only patients with high recurrent disease were included; 38% of all patients were 
chemo/immuno therapy naïve and some of them would also respond well to intravesical 
treatment as monotherapy. Hurle described the significantly higher risk of recurrence for 
multifocal tumours (hazard ratio 1.79, 95% CI 1.23-2.59). The data of the present study did 
not reveal this difference, probably due to the small number of patients. 
Treatment outcome of all eligible patients was related to the risk classification established in 
the European Association of Urology guidelines for diagnosis, therapy and follow-up of 
bladder cancer patients12. Patients were subdivided in two categories, namely high risk (T1, 
GIII, multifocal or highly recurrent, CIS) and intermediate risk (Ta-T1, GI-II, multifocal, >3 
cm diameter). Intermediate risk patients had a longer time to recurrence and a smaller risk of 
recurrence. Only 2 out of 37 intermediate risk patients had recurrent disease in the mean 
follow-up period of 18 months. In the high risk group, 12 out of 53 patients had a recurrence.  
Patients failing BCG are an important but difficult group. O’Donnell studied intravesical 
therapy with interferon-α2B plus low dose BCG in patients with superficial TCC in whom 
BCG alone previously failed23. At a median follow-up of 30 months, 56% and 48% of patients 
were disease free at 12 and 24 months, respectively. The results of the present study show that 
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after 12 and 24 months of follow-up, respectively 77% and 59% of patients, in whom prior 
BCG failed, were disease free. Patients, in whom BCG treatment failed, fare significantly 
worse than patients who were not treated with BCG before.  Naturally this result is due to 
confounding by indication. Patients who were treated previously with BCG have a worse 
prognostic profile than patients who were not treated with BCG. Still, the risk of recurrence in 
the BCG group treated with intravesical chemotherapy combined with hyperthermia, is 
somewhat lower than known from the literature.  
The present study suggests that this prophylactic protocol may be beneficial for patients who 
developed tumour recurrence after previous treatments with intravesical BCG or 
chemotherapy.  
Clearly, a comparative study between hyperthermia combined with mitomycin-C and 
intravesical BCG treatment is necessary. Further studies are also needed to define the best 
candidates for thermo-chemotherapy. 
 
 
Appendix 
 
In this appendix the effectiveness of combined local bladder hyperthermia and intravesical 
chemotherapy for the treatment of high grade (GIII) superficial bladder cancer is evaluated.  
High grade superficial bladder cancer is known to be a biologically aggressive disease. The 
presence of GIII bladder tumours puts the patient in a high risk for progression (odds ratio 
19.9 compared to patients without GIII), disease specific mortality (odds ratio 14)24 and rapid 
recurrence25.  
Patients with GIII bladder tumours (stages Ta or T1) were treated in this study with an 
intravesical combination of MMC and local microwave hyperthermia. Patients were treated in 
either a prophylactic protocol (40mg MMC) following complete transurethral resection of all 
tumours, or in an ablative protocol (80mg MMC) when visible tumour was seen on video-
cystoscopy or bladder biopsies were positive for CIS. Treatment regimen includes 8 weekly 
sessions, followed by 4 monthly sessions.  
Combined thermo-chemotherapy was administered to 52 patients with high grade superficial 
bladder cancer (40 patients with T1 tumour, 11 with Ta, and 3 with concomitant or isolated 
CIS). The characteristics of the patients and treatment are presented in table 4. At a median 
follow-up of 15.2 months (mean 23 months, range 6-90), no stage progression to T2 or 
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disease related mortality has occurred. The overall bladder preservation rate was 86.5%. The 
prophylactic protocol was administrated to 24 patients. After a mean follow-up of 35.3 
months, 15 patients (62.5%) were recurrence free, and the bladder preservation rate was 
95.8%. The ablative protocol was administrated to 28 patients. Complete ablation of the 
tumour was accomplished in 21 patients (75%). After a mean follow-up period of 20 months, 
80.9% of these patients were recurrence free. The bladder preservation rate for the ablative 
group of patients was 78.6%. The recurrence free survival curves are plotted in fig. 8. 
 
 Prophylactic patients Ablative patients 
Patients 
Number of Patients 
 
24 (21 males) 
 
28 (20 males) 
Mean Age (SD) 68 (9) 69 (15) 
Stage of Last Tumour:   
   Ta 5 (21%) 6 (21.5%) 
   T1 19 (79%) 21 (75%) 
   Concomitant CIS 0 2 (7%) 
   CIS alone 0 1 (3.5%) 
Tumour Type:   
   First Episode 1 (4%) 0 
   Recurrent Tumour 16 (70%) 11 (39%) 
   Highly Recurrent* 7 (26%) 17 (61%) 
   Average Number of  
   Previous TURBTs’ (SD) 
 
3(3) 
 
4(2) 
Prior intravesical Therapy:   
    BCG 12 (50%) 17 (60.1%) 
    Intravesical chemotherapy 12 (50%) 11 (39.3%) 
    No prior instillation 3 (12.5%) 8 (28.6%) 
Treatment 
Mitomycin-C dose: 
  
   40 mg 20  3 
   80 mg 3  23 
Epirubicin 50 mg 1  3 
Average Number of  
Treatment Sessions (SD) 
 
11 (2) 
 
9 (3) 
* More than 3 episodes within the last 24 months 
 
Table 4.   Characteristics of patients and treatments 
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Figure 8.  Recurrence-free rates in patients treated with the prophylactic protocol and in patients who 
were complete responders to the ablative protocol.  
 
The care of a patient with high grade (GIII) superficial bladder cancer is one of the most 
challenging tasks in urologic oncology. The main intention of this treatment is to avoid 
tumour progression with its associated morbidity and mortality. Bladder preservation is the 
second intention. Early cystectomy complies well with the first aim but not with the second27-
29. In the absence of reliable histologic or molecular markers for progression, bladder 
preservation is preferred by most urologists and patients30;31.  
Adjuvant intravesical immunotherapy with attenuated tuberculosis vaccine BCG has proved 
effective and has become the standard adjuvant treatment for these patients5, and a useful 
modality in delaying cystectomy32. The recurrence free rate, progression rate, disease specific 
mortality and bladder preservation rate for patients with GIII tumours are presented in table 5. 
In a recent meta-analysis it was shown that treatment with intravesical BCG decreases 
superficial tumour recurrence and progression. Nevertheless no effect on patients’ survival 
was documented6. 
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Bladder 
Preservation 
Rate 
Disease 
Specific 
Survival 
Progression 
Free 
Survival 
Recurrence 
Free 
Survival 
 Follow-up 
Months 
median 
(range) 
 
Population 
Patients 
(N)  Stage 
and grade 
Author
64% 66% 47% - 184  
(159-203) 
86/high risk Cookson et 
al.28 
92% 94% 85.2% 67% 76  
(30-197) 
81/T1G3 Pansadoro et 
al.33 
- - 75.5% 67.3% 71  
(max. 147) 
49/T1G1-3 Kondylis et 
al.30 
71.9% 87.5% 75% 71.9% 58.4 
(24-156) 
32/TaG3 Lebret et al.34 
88.4% 95.3% 83.7% 72.1% 52.5  
(30-96) 
43/T1G3 Bogdanovic 
et al.35 
88% 91.3% 88% 54% 45 
(18-120) 
69/T1G3 Kulkarni et 
al.32 
100% 100% 97.6% 75% 40  
(11-72) 
41/T1G3, 
TaG2-3 
Iori et al.36 
86.3% 90.2% 86.3% 86.3% 33  
(3-63) 
51/T1G3 Hurle et al.37 
72.7% 89% 81.2% 73% 28  
(5-141) 
44/T1G3 Brake et al.38 
93% 100% 100% 71% 15.2  
(6-90) 
 
45/T1G3, 
TaG3 
Current study* 
 
* Includes 45 patients that entered the follow-up program 
 
Table 5.   The results of treatment with BCG (one or two courses) in patients with high risk superficial 
bladder cancer, and the results of the current study 
 
 
The disease free survival of patients in the two treatment arms was similar (fig.8) suggesting a 
similar biologic behaviour of the cancer in both groups. A bias in favour of patients in the 
ablative arm may be present however, since seven patients in the ablative arm classified as 
“non-responders” were excluded from this analysis.  
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The combined thermo-chemotherapy was tolerated relatively well. Most treatment side effects 
were localized and transient. The observation of posterior wall thermal reaction found on 
cystoscopy in two-thirds of the patients has been reported already and is probably due to the 
energy beam heating this wall. This phenomenon is self limited26.  
Systemic effects were rare as expected from the low absorption rate of MMC from the bladder 
into the blood. A maximal concentration of 69 ng ml-1 was documented under ablative 
treatment which is far below the threshold concentration for myelosuppression (400 ng ml-1 
)20. 
With longer follow-up, tumour progression may also be found after thermo-chemotherapy. 
However, as shown by Solsona et al, patients’ prognosis can be usually safely determined on 
the 3 months cystoscopy result following adjuvant BCG treatment in a similar patient 
population39.  
Patients that failed BCG therapy are at a considerably higher risk for tumour progression that 
may be as high as 60%, and disease related mortality of up to 40%40. Two thirds of our 
patients were BCG failures and 23 failed intravesical chemotherapy putting them in a 
considerably high risk group.  These patients responded well to thermo-chemotherapy, and 
their response rate was not inferior to BCG naïve patients. This is probably due to a direct 
cytotoxic effect of thermo-chemotherapy that does not involve cytokine production or 
recruitment of other components of the immune system.  
The combined analysis of treatment outcome of patients with T1 and Ta tumours may be 
criticized. The justification for this comes from recent studies showing that GIII tumours have 
the same biologic behaviour regardless of stage. In a multivariate analysis of a large cohort of 
patients by Millan-Rodriguez et al it was shown that the presence of GIII is the main predictor 
of outcome in patients with superficial bladder cancer and that tumour stage has no 
independent influence on patients’ outcome24. The data presented in table 5 also supports this 
concept. The recurrence rate, progression rate and disease specific mortality of patients 
suffering from TaGIII and T1GIII are similar.  
Who should be considered a candidate for thermo-chemotherapy? As far as GIII tumours are 
concerned, the prophylactic protocol may be beneficial for patients who developed tumour 
recurrence after previous treatments with intravesical BCG or chemotherapy. The ablative 
protocol may be considered in patients suffering from refractory superficial bladder tumour 
who wish to preserve their bladder and for patients whose general health condition prohibits 
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radical cystectomy. In any case the patient must understand his risk for progression and the 
need to adhere to the follow-up protocol.  
Is thermo-chemotherapy more effective than BCG as a first line for prophylaxis? This 
question can be answered only by a prospective randomized trial. Protocol 101.2 is recruiting 
patients at present, in an attempt to answer this question. 
 
 
Conclusion 
 
Microwave induced hyperthermia combined with MMC seems to be a safe and effective 
approach even when other treatments have failed. Ablation of high grade bladder tumours is 
feasible, achieving complete response in about three quarters of the patients. 
Whether thermo-chemotherapy is more effective compared to BCG treatment will have to be 
studied in a prospective randomized trial. Larger prospective randomized multicentre trials 
with longer follow-up are required to validate the results presented before. 
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Summary and discussion 
 
Introduction 
 
In Europe, bladder cancer is the fourth most frequent cancer among men, accounting for about 
7% of all cancers. The incidence of bladder cancer increases with age and is 2 to 3 times more 
common in men. The mortality rate (11 per 100,000 men and 4 per 100,000 women) is 
relatively low because more than 90% of all malignant bladder tumours are transitional cell 
carcinomas of which two third is superficial and one third is muscle invasive. The term 
superficial bladder cancer refers to Ta, T1, and Tis lesions of any grade. Because the 
recurrence rate and potential for progression are different among these lesions, the global term 
of superficial bladder cancer is oversimplified. Approximately 70% of superficial lesions 
present as stage Ta, 20% as T1, and 10% as carcinoma in situ (CIS). Tumour grade and stage 
clearly have an influence on tumour recurrence and progression. Low grade Ta lesions recur 
at a rate of 30% to 70% and have approximately a 5% chance of progression, whereas high 
grade T1 lesions recur in more than 80% of cases and progress in 50% of patients within 3 
years. Tumour size, the number of lesions, reaction to intravesical therapy, stage, grade, 
presence of CIS and recurrence anywhere in the bladder at first follow-up cystoscopy after 
TUR are the most important prognostic factors for time to progression. The risk classification 
established in the European Association of Urology guidelines for diagnosis, therapy and 
follow-up of bladder cancer patients is based on the treatment outcome. Patients are 
subdivided in three categories, namely low risk (single primary bladder tumours; TaGI or 
TaGII), intermediate risk (Ta-T1; GI-II; multifocal; >3 cm diameter) and high risk (T1; GIII; 
multifocal or highly recurrent; CIS). 
The principal technique for the diagnosis and treatment of all superficial bladder lesions is 
endoscopic management, generally by cystoscopy and TUR. Intravesical therapy can 
subsequently serve as adjuvant treatment, as ablative treatment for residual disease, or as 
prophylaxis. The goal of intravesical therapy with chemotherapeutic or immunotherapeutic 
agents is to decrease recurrence, prevent progression, and eradicate residual disease after 
TUR. BCG immunotherapy has established itself as the most successful intravesical agent for 
the treatment of multiple forms of superficial bladder cancer. It is an attenuated 
mycobacterium that has been used as a vaccine for tuberculosis and that has also 
demonstrated antitumour activity in several different cancers. Multiple trials have 
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demonstrated the significant efficacy and impact of BCG in treating superficial bladder 
cancer. Nevertheless, intravesical BCG treatment shows more and more serious side effects 
than intravesical chemotherapy. So, the ideal intravesical agent would be as effective as 
intravesical BCG with minimal local and systemic toxicity as in intravesical chemotherapy.  
In this thesis new treatment options for superficial bladder tumours are studied. Since one 
immediate post-operative instillation with mitomycin-C (MMC) or epirubicin in patients with 
low grade superficial bladder cancer reduces the recurrence rate with 50%, new treatment 
options are not needed in this group of patients. So this thesis concentrates on patients with 
intermediate or high risk superficial bladder tumours. All these patients should be treated 
adjuvant with intravesical immunotherapy or chemotherapy. 
Intravesical chemotherapy is not new. It was initially described in 1900 when silver nitrate 
was used as a therapeutic agent. The apparent value of the different cytostatic agents used 
intravesically since the 1960s when they became widely accepted, are described in chapter 2 
of this thesis. ThioTEPA was the first drug shown to be effective for the treatment of 
superficial bladder cancer when given intravesically. Currently it is no longer frequently used 
due to its toxicity and limited efficacy. Other rarely used intravesical agents are epodyl and 
doxorubicin. Due to the limited efficacy, these agents are also no longer frequently used. 
Agents which are currently often used intravesically are epirubicin and MMC. The efficacy of 
epirubicin seems similar to other chemotherapeutic agents, however, with less drug induced 
cystitis. The efficacy of MMC seems higher than other chemotherapeutic agents, but at the 
cost of more side effects, among these the characteristic allergic skin reaction. More new-
fangled agents are pirarubicin, gemcitabine and EOquinTM (EO9). Preliminary results showed 
that pirarubicin is an effective agent, but additional follow-up and studies are needed. 
Gemcitabine, EO9 as well as the combination local hyperthermia and chemotherapy are 
mentioned below.  
 
 
Basic and Preclinical Research 
 
The chapters 3 to 5 cover the preclinical part of this thesis. In chapter 3 the effect of 
hyperthermia on the cytotoxicity of four currently used chemotherapeutic agents is studied in 
four human bladder cancer cell lines. These cell lines display phenotypes associated with well 
differentiated, moderately differentiated and poorly differentiated bladder cancer cells. The 
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influence of chemotherapy and temperature on cell survival was determined by an MTT 
assay. This assay is fast, cheap and has a good reproducibility. A decrease of viable cells was 
demonstrated with increasing concentrations chemotherapy and increasing temperatures. The 
most potent drug in this in vitro study was the novel bio reductive drug EO9. The low LD50 
combined with the significant synergy under hyperthermic conditions makes EO9 the most 
promising agent in this in vitro study. Nevertheless, under hyperthermic conditions the 
synergism with epirubicin was superior to the use of EO9. 
Chapter 4 deals with the pharmacokinetics of intravesically applied gemcitabine in pigs. In 
this preclinical in vivo study the deoxycytidine analogue gemcitabine is studied in female 
pigs. The animals showed no signs of deterioration of their well-being. In none of the pigs 
systemic absorption was seen. Histology showed in all cases normal bladder wall histology, 
except some cases with mild signs of infection. The use of intravesical gemcitabine in pigs 
was safe in all aspects studied, without systemic absorption. The successor of this study is the 
phase I and pharmacokinetic study in patients with superficial bladder cancer. 
In chapter 5 the urothelial effects of hyperthermia and MMC are described. In this study 15 
patients facing cystectomy were included. Five groups of three patients each were formed. 
Group 1 was treated two days prior to cystectomy with solely MMC; group 2 was treated two 
days prior to cystectomy with solely hyperthermia; group 3 was treated two days prior to 
cystectomy with thermo-chemotherapy; group 4 had been treated the last 3 months before 
cystectomy with a cycle of thermo-chemotherapy and group 5 served as control, patients did 
not receive any treatment prior to cystectomy. Of all patients initial biopsies and tumour tissue 
obtained with cystectomy were used for histopathological diagnosis and 
immunohistochemical analysis of Ki-67 and p53. Six out of nine patients treated with 
hyperthermia showed a decrease in proliferation activity in the tumour tissue samples. The 
MMC group showed in one patient a decrease in proliferation activity, whereas in the control 
group no decrease was observed. As regards p53, seven out of nine patients treated with 
hyperthermia showed a decrease in p53 activity, in other words a lower expression of mutant 
p53. The control group and the MMC group did not show any differences concerning p53.  
Since the inhibition of proliferation activity is one of the most important goals in cancer 
treatment this makes thermo-chemotherapy a promising intravesical treatment. Furthermore 
the current results suggest that thermo-chemotherapy could be an effective treatment in 
patients with a p53 tumour suppressor gene mutated tumour.   
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Clinical Research 
 
The chapters 6 to 8 cover the clinical part of this thesis. Chapter 6 deals with the results of the 
phase I and pharmacokinetic study of intravesical gemcitabine. In this study 3, 4 and 3 
patients were treated with 1000, 1500 and 2000 mg gemcitabine respectively, of which 2, 3 
and 1 patient had highly recurrent tumours before treatment. Seven patients experienced side 
effects which were reversible, non-limiting and WHO 1. Haematology showed only one case 
of drop in white blood cell count (lowest dose level, after the first instillation). Gemcitabine 
plasma levels were immeasurable or low, with peak levels between 30 and 60 minutes, 
decreasing after more instillations. The metabolite difluorodeoxyuridine reached levels of at 
most 5 µM, indicating a very low passage of the drug to the systemic circulation. Intravesical 
gemcitabine in the dose used has minimal and reversible side effects. Plasma evaluation 
indicates that its intravesical use is safe. Early efficacy results (maximum follow-up 36 
months) of this study underline the potential of intravesical gemcitabine in several patient 
groups with superficial bladder cancer. Further studies have to show the optimal dose and 
schedule, as well as the best indication for intravesical gemcitabine.  
Chapter 7 describes the results of the phase II marker lesion study with the use of intravesical 
EO9 in superficial bladder cancer patients. In this study forty-six patients with multiple pTa or 
pT1 bladder tumours were treated with 6 instillations EO9 at weekly intervals. All visible 
tumours were resected before starting intravesical instillations except one marker tumour. 
Response was determined 2 to 4 weeks after the last instillation. Complete response (CR) was 
defined as complete destruction of the marker lesion, confirmed by negative biopsy at the site 
of the tumour marker and no new tumours elsewhere. In 30 cases the response was 
histologically proven complete. One patient withdrew informed consent and refused the last 
treatment due to side effects. This patient had a clinical complete response. Local side effects 
were comparable with side effects due to other chemotherapeutic instillations such as MMC 
and epirubicin, but less severe and less frequent than due to BCG instillations, concluding that 
intravesical EO9 is an efficacious treatment in patients with superficial bladder tumours. 
Furthermore, the marker lesion concept is safe and feasible for the objective evaluation of 
antitumour activity of intravesical administered EO9. The promising results will be tested in 
another phase II study focussing solely on patients with high grade superficial bladder cancer. 
This intravesical agent has the potency to become a standard intravesical treatment in patients 
suffering from superficial bladder cancer. 
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In chapter 8 the efficacy results of a clinical prophylactic thermo-chemotherapy study are 
presented. Ninety eligible patients received adjuvant treatment with a combination of MMC 
and local microwave hyperthermia. All patients had multiple or recurrent Ta or T1 transitional 
cell carcinoma of the bladder and were classified as intermediate or high risk according to 
EAU criteria. In total, 41 patients were BCG failures. The treatment regimen included 6 to 8 
weekly sessions followed by 4 to 6 monthly sessions. Follow-up consisted of video-
cystoscopy and urine cytology every 3 months. All patients were observed for a period of 2 
years. Kaplan-Meier analyses of the total group (N=90) indicated that 1 year after treatment 
only 14.3% (SE 4.5%) of all patients experienced a recurrence. After 2 years of follow-up the 
risk of recurrence was 24.6% (SE 5.9%). No progression in stage and grade was observed. So, 
microwave induced hyperthermia combined with MMC has promising value in intermediate 
or high risk superficial bladder cancer patients compared to literature data of BCG and/or 
intravesical chemotherapy, particularly where other treatments, i.e. BCG, have failed. 
The appendix of this chapter describes the effectiveness of combined local bladder 
hyperthermia and intravesical chemotherapy for the treatment of patients with high grade 
(GIII) superficial bladder cancer. Patients with GIII bladder tumours (stages Ta or T1) were 
treated with a combination of MMC and local microwave hyperthermia in either a 
prophylactic schedule (40mg MMC) following complete transurethral resection of all 
tumours, or in an ablative schedule (80mg MMC) when visible tumour was seen on video-
cystoscopy or bladder biopsies were positive for CIS. Combined thermo-chemotherapy was 
administered to 52 patients with high grade superficial bladder cancer. At a median follow-up 
of 15.2 months (mean 23 months, range 6-90), no stage progression to T2 or disease related 
mortality has occurred. Bladder preservation rate was 86.5%. Prophylactic protocol was 
administrated to 24 patients. After a mean follow-up of 35.3 months, 15 patients (62.5%) 
were recurrence free, and bladder preservation rate was 95.8%. The ablative protocol was 
administrated to 28 patients. Complete ablation of the tumour was accomplished in 21 
patients (75%). After a mean follow-up period of 20 months, 80.9% of these patients were 
recurrence free. Bladder preservation rate for the ablative group of patients was 78.6%. Out of 
these results the conclusion can be drawn that thermo-chemotherapy has a beneficial 
prophylactic effect in patients suffering from GIII superficial bladder cancer. Ablation of high 
grade bladder tumours is feasible, achieving complete response in about three quarters of the 
patients. The question rises if prophylaxis with thermo-chemotherapy is more effective than 
with BCG. Clearly, a comparative study between thermo-chemotherapy and intravesical BCG 
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is necessary. Currently, protocol 101.2 is recruiting patients in an attempt to answer this 
question.  
Overall, thermo-chemotherapy is the intravesical chemotherapy treatment with the highest 
efficacy results. Does this outcome suggest that all patients should be treated initially with 
thermo-chemotherapy? Looking at health economics, bladder cancer is the fifth most 
expensive cancer in industrialized areas such as the United States and Western Europe 
(Botteman et al., Pharmacoeconomics 2003). Per patient the cost from diagnosis until death 
are even the highest among all cancer types. Since the cost of thermo-chemotherapy are a 
multiple of the costs of regular intravesical chemotherapy it is unclear if the decrease in 
recurrence rate on the long term justifies this far more expensive treatment. A cost-benefit 
analysis is required to answer this question. In my opinion thermo-chemotherapy is a 
treatment option that should be used in patients who failed regular intravesical chemotherapy 
or immunotherapy treatment. The increased cost and increased number of side effects require 
patient selection. In the near future more studies are needed to define the best candidates for 
thermo-chemotherapy.  
Looking at the previous, in literature discussed long-term analysis regarding the effectiveness 
of several intravesical chemotherapeutic agents, it is sobering. Although short term tumour 
recurrence is on average decreased by 17% with the use of intravesical chemotherapy, this 
effect deteriorates with long term follow-up. In a meta-analysis of EORTC and Medical 
Research Council the reduction in recurrence among those treated with intravesical 
chemotherapy was only 7% after a mean monitoring period of 7.7 years. Furthermore, the 
progression rate was not influenced by intravesical chemotherapy.  Hopefully the new 
treatment options mentioned in this thesis give better long term results regarding recurrence 
and progression rate. Of all clinical studies mentioned in this thesis the long term follow-up 
results will be analysed in the forthcoming years.  
Finally, some future treatment options are discussed. The first future treatment option, worth 
investigating, is the combination therapy EO9 with hyperthermia. In vitro results show that 
due to the low LD50 and the significant synergy, EO9 is the most promising agent in thermo-
chemotherapy. However, clinical studies are needed to determine the feasibility of this new 
combination therapy in bladder cancer patients. This study should certainly focus on side 
effects of this combination, particularly on chemical cystitis and haematuria. Probably the 
dose EO9 used in this combination therapy should be reduced. 
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Another interesting future treatment is photodynamic therapy (PDT) using sequential 5-
aminolaevulinic acid (ALA) and gemcitabine, epirubicin or EO9. The first results with MMC 
are recently published by Skyrme et al (BJU 2005). This therapy has potential for managing 
high risk superficial bladder cancer and especially CIS of the bladder. Possibly, the treatment 
with other chemotherapeutic agents shows a higher efficacy and a lower toxicity. Time will 
tell! 
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Samenvatting en discussie 
 
Inleiding 
 
Blaaskanker is in Europa de vierde meest frequent voorkomende vorm van kanker onder 
mannen. Ongeveer 7% van alle mannelijke patiënten met kanker heeft blaaskanker. De 
incidentie van blaaskanker neemt toe met de leeftijd en komt twee tot drie keer vaker voor bij 
mannen. Het sterftecijfer ten gevolge van blaaskanker is relatief laag (11 per 100.000 mannen 
en 4 per 100.000 vrouwen), omdat meer dan 90% van alle maligne blaastumoren 
overgangscelcarcinomen zijn waarvan tweederde oppervlakkig en eenderde spierinvasief. De 
term oppervlakkig blaascarcinoom refereert aan Ta, T1 tumoren van elke graad of carcinoma 
in situ. Daar het recidiefpercentage en de progressiekans van de genoemde tumoren sterk kan 
verschillen is de globale term ‘oppervlakkig blaascarcinoom’ te veel vereenvoudigd. 
Ongeveer 70% van de oppervlakkige tumoren presenteren zich als Ta, 20% als T1 en 10% als 
carcinoma in situ (CIS). Stadium en graad van de tumor zijn van invloed op de mate van 
recidivering en progressie. Laaggradige Ta tumoren recidiveren in 30 tot 70% van de gevallen 
en hebben ongeveer 5% kans op progressie, terwijl hooggradige T1 tumoren in meer dan 80% 
van de gevallen recidiveren en in de helft van de gevallen binnen 3 jaar spierinvasief worden. 
De tumorgrootte, het aantal tumoren, de reactie op de intravesicale therapie, stadium, graad, 
de aanwezigheid van CIS en een recidief ergens in de blaas bij de eerste controlescopie na de 
transurethrale resectie (TUR) zijn belangrijke prognostische factoren voor de tijd tot 
progressie. De risicoclassificatie van de European Association of Urology voor patiënten met 
blaaskanker is gebaseerd op behandelresultaten. Patiënten worden onderverdeeld in drie 
categorieën, te weten laag risico (solitaire, primaire blaastumoren; TaGI of TaGII), 
intermediair risico (Ta-T1; GI-II; multifocaal; >3cm diameter) en hoog risico (T1; GIII; 
multifocaal of hoog recidiverend; CIS).  
De meest fundamentele techniek voor diagnose en behandeling van alle oppervlakkige 
blaastumoren is de endoscopische techniek, gewoonlijk middels cystoscopie en TUR. In 
navolging daarop kan intravesicale therapie dienen als adjuvante behandeling, als ablatieve 
behandeling voor resttumor of als profylaxe. Het doel van de intravesicale therapie met 
chemotherapie of immunotherapie is het verlagen van de recidieffrequentie, het voorkomen 
van progressie en het doen verdwijnen van resttumor na transurethrale resectie. BCG 
immunotherapie wordt beschouwd als het meest succesvolle intravesicale middel voor de 
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behandeling van diverse vormen van oppervlakkige blaascarcinomen. Het is een verzwakte 
mycobacterie die wordt gebruikt als vaccin voor tuberculose en tevens antitumor activiteit liet 
zien in diverse kwaadaardige ziekten. Meerdere studies hebben een significante 
werkzaamheid en impact van BCG aangetoond bij de behandeling van oppervlakkige 
blaascarcinomen. Desalniettemin laat BCG meer en ernstigere bijwerkingen zien dan 
intravesicale chemotherapie. Het meest ideale intravesicale geneesmiddel tegen oppervlakkige 
blaastumoren zou dus zo effectief als BCG moeten zijn met minimale locale en systemische 
bijwerkingen zoals intravesicale chemotherapie.  
In dit proefschrift worden de resultaten van studies naar nieuwe behandelmethoden voor het 
oppervlakkige blaascarcinoom beschreven. Daar een directe postoperatieve instillatie met 
mitomycine-C (MMC) of epirubicine in patiënten met een laaggradig oppervlakkig 
blaascarcinoom de recidiefkans met 50% verminderd zijn nieuwe behandelopties niet nodig in 
deze patiëntengroep. Dit proefschrift concentreert zich dan ook op patiënten met een 
intermediair- of hoog risico oppervlakkig blaascarcinoom. Deze patiënten worden normaliter 
adjuvant behandeld met een serie intravesicale immunotherapie of chemotherapie.  
Intravesicale chemotherapie is niet nieuw. Het werd voor het eerst beschreven in 1900 toen 
zilver nitraat gebruikt werd als therapeutisch middel. De waarde van de verschillende sinds 
1960 intravesicaal toegepaste cytostatica worden beschreven in hoofdstuk 2 van dit 
proefschrift. ThioTEPA was het eerste middel dat effectief bleek voor de intravesicale 
behandeling van het oppervlakkige blaascarcinoom. Thans wordt dit middel zelden gebruikt 
in verband met de toxiciteit en beperkte effectiviteit. Andere weinig toegepaste behandelingen 
zijn epodyl en doxorubicine. Vanwege de beperkte werkzaamheid worden deze middelen nog 
maar zelden gebruikt. Chemotherapeutica die thans vaak intravesicaal worden toegepast zijn 
epirubicine en MMC. De werkzaamheid van epirubicine is vergelijkbaar met andere 
chemotherapeutica, echter met minder chemotherapeutica geïnduceerde cystitis. De 
werkzaamheid van MMC lijkt beter dan die van andere chemotherapeutica, echter wel met 
meer bijwerkingen, waaronder de karakteristieke allergische huidreactie. Nieuwere middelen 
zijn pirarubicine, gemcitabine en EOquinTM (EO9). Voorlopige resultaten laten zien dat 
pirarubicine een effectief middel is, additionele follow-up studies zijn echter noodzakelijk. 
Gemcitabine, EO9 en de combinatie lokale hyperthermie en chemotherapie worden hieronder 
beschreven.  
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Basaalwetenschappelijk en Preklinisch Onderzoek 
 
De hoofdstukken 3 tot en met 5 beslaan het preklinische deel van dit proefschrift. In 
hoofdstuk 3 wordt het effect van hyperthermie op de cytotoxiciteit van vier momenteel 
intravesicaal toegepaste chemotherapeutica bestudeerd op vier humane blaaskanker cellijnen. 
Deze cellijnen hebben een fenotype dat geassocieerd wordt met goed gedifferentieerde, matig 
gedifferentieerde en slecht gedifferentieerde blaaskankercellen. De invloed van 
chemotherapie en temperatuur op de overleving van cellen wordt bepaald met een MTT 
analyse. Deze analyse is snel, goedkoop en heeft een goede reproduceerbaarheid. Een afname 
van de levende cellen wordt aangetoond met toenemende concentraties chemotherapie en 
toenemende temperaturen. Het meest potente middel in deze in vitro studie is het nieuwe 
bioreductieve geneesmiddel EO9. De lage LD50 gecombineerd met de significante synergie 
onder hyperthermische condities maakt EO9 een veelbelovend middel in deze in vitro studie. 
Desalniettemin, is onder hyperthermische condities de synergie met epirubicine superieur ten 
opzichte van EO9.  
In hoofdstuk 4 worden de farmacokinetische resultaten beschreven van intravesicaal 
toegepaste gemcitabine in varkens. In deze preklinische in vivo studie wordt het 
deoxycytidine analoog gemcitabine bestudeerd in vrouwelijke varkens. De dieren lieten geen 
tekenen zien van verslechtering van welzijn. Geen enkel varken vertoonde systemische 
absorptie. Histologische analyse liet in alle gevallen een normale blaaswand histologie zien, 
behalve in enkele gevallen wat milde tekenen van infectie. Het gebruik van intravesicale 
gemcitabine in varkens is veilig in alle bestudeerde aspecten, zonder systemische absorptie. 
De opvolger van deze studie is de fase I en farmacokinetische studie in patiënten met 
oppervlakkige blaascarcinomen.  
In hoofdstuk 5 wordt het effect van hyperthermie en MMC op het urotheel beschreven. In 
deze studie zijn 15 patiënten ingesloten die een cystectomie moesten ondergaan. Patiënten 
zijn verdeeld over 5 groepen van ieder 3 patiënten. Groep 1 werd twee dagen voor de 
cystectomie behandeld met intravesicale MMC; groep 2 werd twee dagen voor de cystectomie 
behandeld met uitsluitend intravesicale hyperthermie; groep 3 werd twee dagen voor de 
cystectomie behandeld met thermo-chemotherapie; groep 4 werd binnen drie maanden voor 
de cystectomie behandeld met een cyclus thermo-chemotherapie en groep 5 fungeerde als 
controlegroep, deze patiënten kregen geen voorbehandeling voor cystectomie. Van alle 
patiënten werden initiële biopten en tumorweefsel, verkregen tijdens cystectomie, gebruikt 
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voor immunohistochemische analyse van Ki-67 and p53. Zes van de negen patiënten 
behandeld met hyperthermie lieten een afname van de proliferatie activiteit in het 
tumorfragment zien. De MMC groep liet in één patiënt een afname in de proliferatie activiteit 
zien, terwijl in de controle groep geen veranderingen zijn waargenomen. Wat betreft p53, 
zeven van de negen patiënten behandeld met hyperthermie lieten een afname in p53 activiteit 
zien, met andere woorden een lagere expressie van het mutante p53. De controle groep en de 
MMC groep liet geen veranderingen zien wat betreft p53 expressie.  
Het feit dat de afname in proliferatie activiteit een van de grootste doelen is in de behandeling 
van kanker maakt thermo-chemotherapie een veelbelovende intravesicale behandeling. 
Bovendien suggereren de huidige resultaten dat thermo-chemotherapie een effectieve 
behandeling kan zijn bij patiënten met een p53 tumorsupressor-gen gemuteerde tumor.  
 
 
Klinisch Onderzoek 
 
De hoofdstukken 6 tot en met 8 beslaan het klinische gedeelte van dit proefschrift. Hoofdstuk 
6 beschrijft de resultaten van de fase I en farmacokinetische studie van intravesicale 
gemcitabine. In deze studie worden 3, 4 en 3 patiënten behandeld met respectievelijk 1000, 
1500 en 2000 mg gemcitabine. Van deze patiënten hadden 2, 3 en 1 patiënt hoog 
recidiverende tumoren voor de start van de behandeling. Zeven patiënten kregen bijwerkingen 
die allen reversibel, voorbijgaand van aard en WHO graad 1 zijn. Haematologische analyse 
liet slechts in één geval een leukocyten daling zien (laagste dosis, na de eerste instillatie). 
Gemcitabine plasma waarden waren onmeetbaar of laag, met piekwaarden tussen 30 en 60 
minuten, afnemend na meerdere instillaties. De metaboliet difluorodeoxyuridine bereikte 
maximaal het niveau van 5µM, wat een hele lage passage van het geneesmiddel naar de 
systemische circulatie betekent. Intravesicale gemcitabine in de toegepaste dosis heeft 
minimale en reversibele bijwerkingen. Plasma evaluatie laat zien dat het intravesicale gebruik 
veilig is. Vroege resultaten over de werkzaamheid (maximale follow-up van 36 maanden) 
onderstrepen de potentie van intravesicale gemcitabine in diverse patiëntengroepen met 
oppervlakkige blaastumoren. Andere studies zullen het optimale schema, de dosis en de beste 
indicatie voor intravesicale gemcitabine moeten vaststellen.  
Hoofdstuk 7 beschrijft de resultaten van de fase II markerlaesie studie met intravesicale EO9 
bij patiënten met oppervlakkige blaascarcinomen. In deze studie zijn 46 patiënten met 
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multiple pTa of pT1 blaastumoren wekelijks behandeld met zes instillaties EO9. Alle 
zichtbare tumoren op één na (de markerlaesie) zijn gereseceerd voordat gestart werd met de 
intravesicale instillaties. De respons werd twee tot vier weken na de laatste instillatie 
geëvalueerd. Complete respons werd gedefinieerd als complete destructie van de 
markerlaesie, bevestigd door een negatieve biopsie van de plaats waar de markerlaesie was 
achtergelaten en geen andere recidieven elders in de blaas. In 30 gevallen was er sprake van 
een complete histologisch bewezen respons. Eén patiënt trok het informed consent in en 
weigerde de laatste behandeling vanwege bijwerkingen, Deze patiënt had een klinisch 
complete respons. De lokale bijwerkingen zijn vergelijkbaar met bijwerkingen van andere 
chemotherapeutische instillaties zoals MMC en epirubicine. De bijwerkingen zijn minder 
ernstig en minder frequent als ten gevolge van BCG instillaties. Concluderend kan worden 
gesteld dat intravesicale EO9 een werkzame behandeling is in patiënten met een oppervlakkig 
blaascarcinoom. Bovendien kan worden gesteld dat het markerlaesie concept veilig is en 
toepasbaar is voor een objectieve evaluatie van de antitumor activiteit van intravesicaal 
toegepaste EO9. De veelbelovende resultaten zullen worden getoetst in een andere fase II 
studie die zich volledig richt op patiënten met een hooggradig oppervlakkig blaascarcinoom. 
Dit intravesicale middel heeft de potentie om een standaard behandeling te worden voor 
patiënten met oppervlakkig blaascarcinoom.  
In hoofdstuk 8 worden de resultaten van een klinische profylactische thermo-chemotherapie 
studie beschreven. Negentig evalueerbare patiënten werden behandeld met adjuvante thermo-
chemotherapie. Alle patiënten hadden multiple of recidiverende Ta of T1 
urotheelcelcarcinomen van de blaas en werden geclassificeerd volgens de EAU criteria als 
intermediair- of hoog risico. In totaal zijn er 41 patiënten geïncludeerd, die ondanks BCG een 
recidief ontwikkelden. Het behandelschema omvatte 6 tot 8 wekelijkse behandelingen 
gevolgd door 4 tot 6 maandelijkse behandelingen. Follow-up bestond uit videocystoscopie en 
urinecytologie iedere 3 maanden. Alle patiënten werden gedurende twee jaar geobserveerd. 
Een Kaplan Meier analyse van de totale groep (N=90) liet zien dat 1 jaar na de behandeling 
slechts 14.3% (SE 4.5%) van alle patiënten een recidief had. Na 2 jaar follow-up was het 
risico op een recidief gestegen naar 24.6% (SE 5.9%). Er werd geen progessie in stadium en 
graad gezien. Concluderend is vergeleken met literatuur gegevens van intravesicale BCG 
en/of intravesicale chemotherapie, microgolf geïnduceerde hyperthermie gecombineerd met 
MMC veelbelovend bij patiënten met een intermediair of hoog risico oppervlakkig 
blaascarcinoom, met name als andere behandelingen, bijvoorbeeld BCG, hebben gefaald.  
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Het appendix van dit hoofdstuk beschrijft de werkzaamheid van thermo-chemotherapie voor 
de behandeling van patiënten met een graad III urotheelcelcarcinoom van de blaas. Patiënten 
met GIII blaastumoren (stadium Ta of T1) zijn behandeld met thermo-chemotherapie in een 
profylactisch schema (40mg MMC) in navolging op een TUR van alle tumoren, of in een 
ablatief schema (80mg MMC) als er sprake is van resttumor of als er sprake is van biopten die 
positief zijn voor CIS. Thermo-chemotherapie werd toegepast bij 52 patiënten met 
hooggradig oppervlakkig urotheelcelcarcinoom van de blaas. Bij een mediane follow-up van 
15,2 maanden (mean 23 maanden, range 6-90 maanden) werd geen progressie naar een T2 
tumor of ziekte gerelateerde mortaliteit gezien. De blaas werd in 86,5% behouden. Het 
profylactische protocol werd bij 24 patiënten toegepast. Na een gemiddelde follow-up periode 
van 35,3 maanden waren 15 patiënten (62,5%) vrij van recidieven en werd de blaas in 95,8% 
van de gevallen behouden. Het ablatieve protocol werd toegepast bij 28 patiënten. Complete 
ablatie van de tumor trad bij 21 patiënten (75%) op. Na een gemiddelde follow-up periode 
van 20 maanden was 80,9% van deze patiënten vrij van recidieven. De blaas werd behouden 
in 78,6% van de ablatieve patiënten. Uit deze resultaten kan worden geconcludeerd dat 
thermo-chemotherapie een gunstig profylactisch effect heeft bij patiënten met een GIII 
urotheelcelcarcinoom van de blaas. Ablatie van hooggradige blaastumoren is haalbaar en 
geeft in driekwart van de patiënten een complete respons. De vraag rijst nu of een 
profylactische behandeling met thermo-chemotherapie effectiever is dan een BCG 
behandeling. Een vergelijkende studie tussen thermo-chemotherapie enerzijds en intravesicale 
BCG anderzijds is noodzakelijk. Momenteel worden in het 101.2 protocol patiënten 
ingesloten om deze vraag uiteindelijk te beantwoorden.  
Alle resultaten in beschouwing genomen is thermo-chemotherapy de intravesicale 
chemotherapeutische behandeling met de hoogste werkzaamheid. Wil dat nu zeggen dat alle 
patiënten initieel moeten worden behandeld met thermo-chemotherapie? Binnen de 
gezondheidszorg is blaaskanker de vijfde meest kostbare vorm van kanker in de 
geïndustrialiseerde gebieden zoals de Verenigde Staten en West Europa (Botteman et al., 
Pharmacoeconomics 2003). Per patiënt zijn de kosten van diagnose tot overlijden zelfs de 
hoogste van alle soorten kanker. Gezien de kosten van thermo-chemotherapie een veelvoud 
zijn van de kosten van reguliere intravesicale chemotherapie is het onduidelijk of de afname 
in recidief percentage op de lange termijn deze veel duurdere behandeling rechtvaardigt.  
Een kosten-batenanalyse is noodzakelijk om deze vraag te beantwoorden. Mijns inziens is 
thermo-chemotherapie een behandeloptie die toegepast dient te worden bij patiënten die niet 
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of onvoldoende reageren op reguliere intravesicale chemotherapie of immunotherapie. De 
toegenomen kosten en de toegenomen incidentie van bijwerkingen vereisen selectie van 
patiënten. In de nabije toekomst zijn meer studies noodzakelijk om de beste kandidaten voor 
thermo-chemotherapie te selecteren. 
De voorgaande in de literatuur beschreven lange termijn analyses wat betreft de effectiviteit 
van diverse intravesicale chemotherapeutica zijn bedroevend. Ondanks het feit dat het 
recidiefpercentage bij het gebruik van intravesicale chemotherapie op de korte termijn daalt 
met 17%, verdwijnt dit verschil op de lange termijn. Uit een meta-analyse van de EORTC en 
de Medical Research Counsil blijkt dat de afname in het recidiefpercentage met ongeveer 7% 
daalt na een follow-up periode van 7,7 jaren. Bovendien blijkt dat de progressiekans niet 
beïnvloed wordt door de toepassing van intravesicale chemotherapie. Hopelijk geven de 
nieuwe behandelmethoden die beschreven zijn in dit proefschrift betere lange termijn 
resultaten wat betreft recidiefpercentage en progressiekans. Van alle klinische studies zullen 
de komende jaren de lange termijn follow-up resultaten worden geanalyseerd. 
Tot slot worden enkele mogelijk toekomstige behandelmethoden besproken. De eerste 
toekomstige behandelmethode die onderzoek rechtvaardigt, is de combinatie EO9 en 
hyperthermie. In vitro studies laten zien dat door de lage LD50 en de significante synergie, 
EO9 het meest veelbelovende geneesmiddel is bij thermo-chemotherapie. Desalniettemin zijn 
er klinische studies nodig om de haalbaarheid van deze nieuwe combinatie therapie bij 
patiënten met blaaskanker vast te stellen. Deze studie dient zich zeker ook te concentreren op 
de bijwerkingen van deze combinatie, met name chemische cystitis en haematurie. Naar alle 
waarschijnlijkheid zal de dosering EO9 moeten worden verlaagd in deze combinatie. 
Een andere interessante toekomstige behandeling is photodynamic therapy (PDT) met 
sequentieel gebruikmaking van 5-aminolaevuline zuur (ALA) en gemcitabine, epirubicine of 
EO9. De eerste resultaten met MMC zijn recentelijk gepubliceerd door Skyrme et al. (BJU 
2005). Deze behandeling heeft potentie voor patiënten met een hoogrisico oppervlakkig 
blaascarcinoom en vooral CIS van de blaas. Mogelijk laat de behandeling met andere 
chemotherapeutica een hogere effectiviteit zien bij een lagere toxiciteit. De tijd zal het ons 
leren!
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Misschien is dit wel het meest gelezen stuk van het proefschrift: Het Dankwoord! Zonder de 
illusie te hebben volledig te zijn wil ik graag de volgende personen danken voor hun bijdrage 
in de totstandkoming van dit proefschrift. 
 
Prof. dr. J.A. Witjes, beste Fred. In 2001 heb je mij de mogelijkheid geboden om te starten 
met een promotieonderzoek naar nieuwe behandelmethoden voor het oppervlakkige 
blaascarcinoom. Je vertelde me toen dat blaaskanker je hobby is geworden en inmiddels kan 
ik je zeggen dat ik nu begrijp wat je destijds bedoelde. Ik wil je bedanken voor je enthousiaste 
begeleiding, je voortvarendheid, kritische blik en vooral grote steun.  
 
Prof. dr. J.A. Schalken, beste Jack. De basale research beschreven in dit proefschrift heeft 
plaats gevonden onder jouw toezicht. Het cellijnonderzoek waar ik enthousiast aan begon in 
de veronderstelling binnen enkele maanden resultaat te hebben werd een jarendurend geheel. 
Bedankt voor de mogelijkheden die je me geboden hebt om basale research toe te voegen aan 
mijn voornamelijk klinische proefschrift.  
 
Dr. G. Verhaegh, beste Gerald. Jij hebt mij wegwijs gemaakt in basale research, geen 
makkelijke taak! Ik wil je graag bedanken voor je hulp de afgelopen jaren. 
 
Dr. A. Lev, dear Avigdor. Thank you for your knowledge and support. I enjoyed our basic 
research discussions and I am looking forward to continuing our collaboration.  
 
Prof. dr. L.A.L.M. Kiemeney en Dr. C.A. Hulsbergen-van de Kaa, beste Bart en Christina. 
Bedankt voor de samenwerking op statistisch en histopathologisch gebied. 
 
Drs. Paulina Moonen, beste Paula. Ik had de eer om jou in te mogen werken, althans zo zag jij 
het! Of het nu echt zo’n eer is weet ik niet, maar gezellig was het wel. Ik weet dat er nog heel 
veel werk is blijven liggen en ik hoop dat dat mede een mooie basis kan vormen voor jouw 
proefschrift. Bedankt voor de fijne samenwerking en succes met je carrière. 
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Verder wil ik de medewerkers van het laboratorium voor Experimentele Urologie bedanken. 
Ik weet dat het noemen van namen mogelijk wrijving geeft, desalniettemin wil ik in 
alfabetische volgorde  Dorien, Egbert, Ivar, Janneke, Jeannette, Kees, Miriam, Pim en Renate 
in het bijzonder danken. 
 
De verpleegkundigen van afdeling A10 en A20 evenals de secretaresses Ingeborg, Rian, 
Yvonne en Annie, die me bij iedere TUR moesten bellen, wil ik graag van harte bedanken. 
 
De operatieassistenten van OK 15 en OK 18, en in het bijzonder Anja, Hariëtte, Vanessa en 
Anita die iedere keer toch maar weer begrip op moesten brengen voor het feit dat er diverse 
studies werden uitgevoerd, wil ik hartelijk bedanken. In een tijd waar wachtlijsten en 
arbeidsduurverkorting, een enorme druk legt op het OK personeel brengen jullie toch het 
respect en de energie op deze studies mogelijk te maken. 
 
Het balie-, archief- en verplegend personeel van de poli en het steencentrum wil ik danken 
voor de vooral gezellige fijne samenwerking. Vooral de zogenaamde Synergo-assistentes 
Diana en Moniek: Bedankt voor jullie adequate hulp en vrolijke bijdrage! Tevens wil ik Anita 
en alle Josés van de poli van harte bedanken voor hun oncologische ondersteuning. Het was 
voor mij een leerzame tijd op diverse vlakken.  
 
Alle medewerkers van het secretariaat wil ik bedanken voor de diensten van de afgelopen 
jaren. In het bijzonder wil ik Els danken voor haar (vrije)tijd en inzet.  
 
Een bijzonder woord van dank wil ik richten tot de patiënten. Bedankt voor het vertrouwen en 
bedankt dat enkele van u de afgelopen jaren aan iedere studie naar nieuwe behandelmethoden 
heeft deelgenomen. Zonder uw bijdrage zou dit proefschrift niet tot stand zijn gekomen.  
 
Aan het einde van dit meest gelezen stuk van het proefschrift rest mij nog al mijn vrienden, 
vriendinnen, kennissen en familieleden van harte te danken. In het bijzonder gaat mijn dank 
uit naar Frank Metzemaekers, die veelvuldig de Engelse teksten ‘mocht’ corrigeren (je hebt 
immers niet voor niets Engels gestudeerd), èn Hanneke Dongelmans; beide paranimfen. Peet, 
bedankt voor de tijd die je geïnvesteerd hebt ten behoeve van de omslag en de uitnodigingen. 
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Verder zeker niet te vergeten: Mijn zus Hanneke en mijn vriend(inn)en Hendry, Bas, Ted, 
Madeleine, Brenda, Heidi en Annemarie. 
 
Mijn vader wil ik danken voor zijn nooit aflatende steun op diverse vlakken. Ik weet dat 
kanker een heel diepe wond in jouw leven heeft achtergelaten, evenals in het leven van je 
kinderen. Ik hoop een kleine bijdrage in de bestrijding van kanker te hebben geleverd en wil 
de komende decennia mijn aandacht blijven vestigen op de bestrijding van deze ziekte.  
 
Tot slot wil ik mijn moeder bedanken. Helaas ben je hier niet bij, maar ik weet dat je dit 
fantastisch zou vinden. Bedankt voor alles! 
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